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Abstract
Blood flow to the ovary is an essential part of the ovulatory process. An increase in 
blood flow to the ovary precedes the process of ovulation. Therefore, any factor(s) 
that interfere with blood flow through the ovarian artery, would interfere with the 
ovulatory process and also development of the fertilized ovum. The objective of this 
study was to (1) identify a-adrenergic receptors in the rabbit ovarian vascular bed, (2) 
investigate if such adrenoceptor subtypes are linked to different signal transduction 
mechanisms and (3) study the influence of hormonal changes (induction of ovulation, 
oestrogen treatment and pregnancy) on a  j-adrenoceptor mediated responses.
The studies were conducted using an in vitro perfusion system, where the ovarian 
vascular bed (en bloc) was perfused with Krebs’ solution delivered at a constant flow 
of 6 ml/min using a peristaltic pump. Changes in perfusion pressure which reflected 
peripheral resistance were measured.
The results showed that noradrenaline (NA) induced reproducible dose-dependent 
vasoconstrictor responses which were slightly but not significantly reduced by 
removal of the endothelium. The vasoconstrictor effects were however enhanced by 
L-NOARG but not aminoguanidine indicating modulation of NA responses by 
endothelial NO. Phentolamine (10‘6 M) displaced NA dose-response curve to the 
right without suppressing the Emax. The pKB value was calculated to be 7.7±0.08. 
The rank order of agonist potency was NA ^  oxymetazoline > SDZ NVI 085 >
o r
phenylephrine > methoxamine. Prazosin (10‘ M-10’ M) displaced agonist dose- 
response curves to the right. The pA2/pKB values ranged between 7.27-7.7 against 
NA, phenylephrine, methoxamine and SDZ NVI 085 and were not significantly 
different from each other. Prazosin was, however, significantly less potent against 
oxymetazoline (pA2=6.38). Yohimbine was not effective against NA or
phenylephrine. WB-4101 (10'8M-10'5M) displaced agonist dose-response curves to 
the right. The pA2/pKB values ranged between 7.1-7.9 against NA, phenylephrine, 
methoxamine and SDZ NVI 085. WB-4101 was significantly less potent against 
oxymetazoline (pKB=6.9). SZL-49 (5x1 O^M) but not CEC (SxlO^M-lO^M)
significantly reduced vasoconstrictor responses to all the agonists. Niguldipine
i
g
(10 M) significantly attenuated NA-induced vasoconstriction. These results would 
suggest that a 1A-subtype receptor mediated postjunctional effects of the adrenergic 
agonists.
Electrical stimulation of the perfused preparation produced frequency-dependent 
vasoconstrictor effects which were abolished by 6-OHDA indicating the involvement - 
of adrenergic nerves. The responses were also concentration-dependently antagonized 
by prazosin and WB-4101, while yohimbine reduced the response to electrical 
stimulation by 20% at 10'5M. The vasoconstrictor effect to electrical stimulation 
was also inhibited by SZL-49 but not CEC. These results would suggest that the 
vasoconstrictor responses of the ovarian vascular bed to electrical stimulation are 
mediated via the a 1A-adrenoceptor subtype.
The relative roles of extracellular calcium influx and intracellular calcium release in
the coupling of a  j-adrenoceptor activation, were also investigated. Vasoconstrictor
responses to NA were significnatly reduced in Ca2+-free KH-solution (with or without
EGTA) and after treatment with Ca2+ channel antagonists, verapamil and nifedipine.
The difference in efficacy between NA and SDZ NVI 085 did not show that verapamil
and nifedipine being more potent against SDZ NVI 085. The vasoconstrictor
2+
response to KC1 was abolished by the Ca channel inhibitors. Such results indicate
2+
that the major source of Ca for mediating NA-induced vasoconstriction was from 
the extracellular calcium pool through the activation of ROCs with a probably minor 
role for the intracellular Ca2+ stores, which was found not to be the sarcoplasmic 
reticulum, since ryanodine did not produce any inhibitory effect on the vasoconstrictor 
responses to NA. In addition, TK but not PKC was found to be the intracellular 
second messenger which participates in the signal transduction mechanisms in this 
preparation.
The influence of the hormonal changes on the vascular reactivity to a  j-adrenergic 
agonists was also examined. The results showed an increased sensitivity of the 
ovarian vascular bed to NA and oxymetazoline but not to histamine in rabbits treated 
with 17fl-oestradiol propionate and also during ovulation and pregnancy. Except for 
oxymetazoline, there was no change in the maximum response. In pregnant rabbits,
7 5prazosin (10‘ M) but not yohimbine (10‘ M) displaced NA dose-response curve to 
the right. The pKB value for prazosin against NA was 9.6+0.3. SZL-49 (5x10"* M)
but not CEC (3x10‘5 M) significantly reduced vasoconstrictor response to NA. These 
results are comparable with the corresponding results in control rabbits, indicating the 
predominance of a iA-adrenoceptor subtype. In addition, the vasodilator responses to 
carbachol and SNP were maintained (though not enhanced), and L-NOARG was more 
effective in attenuating the vasodilator response to carbachol compared to contol 
situation, an indication of the enhanced role for EDRF (NO) in rabbits treated with 
17B-oestradiol propionate as well as during ovulation and pregnancy.
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NOS nitric oxide synthase
PA phosphatidic acid
PDGF platelet-derived growth factor
PK protein kinase
PKC protein kinase C
PLC phospholipase C
PMA phorbol 12-myristate 13-acetate
Ptdlns phosphatidylinositol











List of abbreviations V
List of figures xi
List of tables XV
Chapter one Introduction
1.1 Ovarian vascular bed 1
1.1.1 Blood supply to the ovary 1
1.1.2 Innervation of the ovary 1
1.1.3 Adrenergic regulation of ovarian function 4
1.1.4 Ovulation 5
1.1.4.1 Vascular dynamics during ovulation 5
1.2 Classification of alpha-adrenoceptors 6
1.2.1 Concept of a p  and a 2-adrenoceptors 6
1.2.2 Subclassification of a  j -adrenoceptors 7
1.2 .2.1 Concept of a 1H, a 1L and <x1N-adrenoceptor subtypes 7
1.2 .2.2 a iA"> a iB- a 1D-adrenoceptor subtypes 9
1.2.2.3 a lc-adrenoceptors 10
1.2.2.4 Atypical ctj-adrenoceptors 12
1.2.3 Sub-classification of a 2-adrenoceptors 13
1.2.3.1 Pre- versus post-junctional a 2-adrenoceptors 14
1.3 Signal transduction mechanisms 16
1.3.1 2+a  i-Adrenoceptor subtypes and Ca utilization 18
1.4 Influence of the endothelium 23
1.4.1 Early observations of EDRF and its identification as nitric oxide 23
1.4.2 Inhibition of NO synthesis 27
1.4.3 Endothelium-dependent NO-independent relaxation 27
1.4.4 Endothelium-dependent vasoconstriction 28
1.5 Objectives of the study 30
v ii
Chapter two Materials and methods
2.1 Materials used in the study 31
2 .1.1 Drugs 31
2 .1.2 Physiological solutions 32
2.1.3 Choice of animal species 32
2.1.4 Isolation of the ovarian vascular bed 32
2.2 Experimental procedure 34
2 .2.1 Preliminary experiments 38
2 .2 .1.1 Influence of time on the responses to NA 38
2 .2 .1.2 Effects of uptake and B-adrenoceptor blockade on responsiveness to 
NA
38
2.2.1.3 Effects of indomethacin on NA-induced vasoconstriction 38
2.2.1.4 Effects of other agonists on NA-induced vasoconstriction 38
2.2.1.5 Electrical stimulation of the perfused ovarian vascular bed 39
2 .2.2 Influence of the vascular endothelium 39
2 .2 .2.1 Effects of endothelial cell removal on agonist-induced responses 39
2 .2 .2.2 Effects of NOS inhibitors on NA-induced vasoconstriction 39
2 .2 .2 .2.1 Effect of L-NOARG and D-NOARG on NA-induced vasoconstriction 39
22.2.2.2 Effects of aminoguanidine on NA-induced vasoconstriction 40
2.22.3 Effects of NOS inhibitors on agonist-induced vasodilator responses 40
2.2.2A Effects of cyclicGMP inhibition on agonist-induced vasodilator 
responses
40
2.2.3 Identification and characterization of adrenoceptors in the ovarian 
vascular bed
41
2.2.3.1 Identification of adrenergic receptors 41
2.2.3.1.1 Effects of prazosin and yohimbine on agonist-induced responses 41
2.2.3.2 Characterization of a!-adrenoceptor subtypes 42
2.2.3.2.1 Competitive antagonists 42
2.2.3.2.2 Irreversible antagonists 43
2.2.4 Signal transduction mechanisms 44
44
2.2.4.1 Calcium-free solution
2.2.4.2 Calcium channel blocking agents 44
viii
2.2A.3 Effects of inhibitors of intracellular calcium release 45
2.2.4.4 Effects of protein kinase C inhibitors 45
2.2.4.5 Effects of tyrosine kinase inhibitor 45
2.2.5 Effects of hormonal changes on vascular reactivity 46
2.2.5.1 Effects of ovulation induction with HCG 46
2.2.5.2 Effects of 17-B-oestradiol 45
2.2.5.3 Effects of pregnancy 46
2.2.5.4 Experimental procedure 46
2.3 Statistical analysis 47
Chapter three Results
3.1 Preliminary experiments 48
3.1.1 Influence of time on the responses to NA 48
3.1.2 Effects of uptake inhibitors and B-adrenoceptor blockade on 48
responsiveness to NA
3.1.3 Effects of indomethacin 48
3.1.4 Effects of other agonists 48
3.1.5 Effects of electrical stimulation 53
3.2 Influence of the endothelium 58
3.2.1 Effects of endothelial cell removal on agonist-induced responses 58
3.2.2 Effects of NOS inhibitors on NA-induced vasoconstriction 58
3.2.2.1 Effect of L-NOARG and D-NOARG on NA-induced vasoconstriction 58
3.2.2.2 Effects of aminoguanidine on NA-induced vasoconstriction 62
3.2.3 Effects of NOS inhibitors on agonist-induced vasodilator responses 62
3.2.4 Effects of cyclicGMP inhibition on agonist-induced vasodilator 62
responses
3.3 Identification and characterization of adrenoceptors 71
3.3.1 Identification of adrenoceptors 71
3.3.2 Effects of adrenergic agonists on perfusion pressure of the ovarian 71
vascular bed



























Effects of a-adrenoceptor antagonists on electrically-induced 
vasoconstriction






Calcium channel blocking agents
Intracellular calcium antagonist
Protein kinase C inhibitors
Tyrosine kinase inhibitor
Effects of hormones and pregnancy





Influence of the vascular endothelium
Adrenergic receptors in the ovarian circulation
a- or B-Adrenoceptors
a t- or a 2-Adrenoceptors
Subtype(s) of a!-adrenoceptors
Signal transduction mechanisms
Hormonal influences on the ovarian vasculature
Conclusion



























Reproductive system of the female rabbit. 2
Innervation of the human ovary. ^
Generation and action of Ins( 1,4,5)p3 ^
pc
Synthesis of nitric oxide.
Factors causing the release of EDCF(s) in blood vessels 9^
Picture of rabbit ovarian vascular bed in situ.
Picture of an isolated rabbit ovarian vascular bed. 35
Diagram of rabbit ovarian vascular bed being cannulated. ^6
Schematic diagram of the perfusion set-up. 37
Repetitive NA dose-response curves 9^
Effect of uptake and B-adrenoceptors blockade on NA-induced ^
vasoconstriction
Effect of indomethacin on NA dose-response curve 51
Dose-response curve for KC1 52
Dose response curves for bradykinin, angiotensin II and histamine 54
Voltage-response and frequency-response relationship in the perfused rabbit 55 
ovarian vascular bed
Effect of tetrodotoxin on electically stimulated ovarian vasculature 56
A typical trace of electrically stimulated perfused rabbit ovarian vascular bed. 57 
Effect of 6-OHDA on vasoconstrictor response to electrical stimulation and 59
tyramine.
A typical trace of carbachol-induced vasodilatation before and after 50
endothelial removal.
Vasoconstrictor responses to NA and KC1 before and after CHAPS. 51
Effects of L-NOARG and D-NOARG on NA-induced vasoconstriction. 63 
Effects of L-N0 ARG on NA-induced vasoconstriction in de-endothelialized 64 
preparation.
Effects of L-arginine on L-NOARG-induced potentiation of vasoconstrictor 65
responses to NA
























A typical trace of carbachol-induced vasodilatation before and after treatment 
with L-NOARG.
Effects of L-NOARG on carbachol-, SNP- and isoprenaline- induced 
vasodilation.
Effects of LY 83583 on carbachol-induced vasodilation.
A typical trace of the effect of LY 83583 on carbachol-, SNP-and isoprenaine- 
induced vasodilation.
Effects of methylene blue on carbachol- and SNP-induced vasodilation. 
Effects of phentolamine on NA-induced vasoconstriction.
Vasoconstrictor effects of some adrenergic agonists.
A typical trace of oxymetazoline- and NA-induced vasoconstriction 
Effects of isoprenaline before and after raising the basal perfusion pressure. 
Vasodilator effect of isoprenaline before and after treatment with propranolol. 
A typical trace of isoprenaline-induced vasoconstriction before and after 
treatment with phentolamine.
Effects of prazosin on NA-, phenylephrine- and oxymetazoline-induced 
vasoconstriction.
Effects of prazosin on methoxamine- and SDZ NVI 085-induced 
vasoconstriction.
Effects of yohimbine on NA- and phenylephrine-induced vasoconstriction. 
Effects of prazosin and yohimbine on responses to electrical stimulation. 
Effects of WB-4101 onNA-, phenylephrine- and oxymetazoline-induced 
vasoconstriction.
Effects of WB-4101 on methoxamine- and SDZ NVI 085-induced 
vasoconstriction.
Effects of niguldipine on NA-induced vasoconstriction.
Effects of WB-4101 on vasoconstrictor response to electrical stimulation. 
Effects of CEC on NA- and oxymetazoline-induced vasoconstriction.
Effects of SZL-49 on NA-, phenylephrine- and oxymetazoline-induced 
vasoconstriction.
Effects of SZL-49 on methoxamine- and SDZ NVI 085-induced 
vasoconstriction.
x ii
46 Effects of SZL-49 and CEC on vasoconstrictor response to electrical 96 
stimulation.
2+
47 Effects of Ca -free KH-solution on NA-induced vasoconstriction. 97
48 A typical trace of time-dependent loss of NA-induced vasoconstriction in 98
Ca2+-free KH-solution.
49 Effects of Ca2+-free solution on NA-induced at different time intervals. 99
50 Effects of verapamil and nifedipine on NA-induced vasoconstriction. 101
51 Effects of verapamil and nifedipine on SDZ NVI 085- induced 102
vasoconstriction
52 Effects of verapamil and nifedipine on KCl-induced vasoconstriction. 103
53 Effects of ryanodine on NA-induced vasoconstriction. 104
54 Effects of HA-1077 B on NA-induced vasoconstriction. 105
55 Effects of polymyxin B on NA-induced vasoconstriction. 107
56 Effect of HA-1077 and polymyxin B on vasoconstrictor responses to CaCl2 in 108
80 mM KC1 depolarized KH-solution.
57 Effects of genistein on NA-induced vasoconstriction. 109
5 8 Vasoconstrictor responses to NA and oxymetazoline in HCG-treated rabbits. 111
59 Vasoconstrictor responses to histamine in control and HCG-treated rabbits. 113
60 Effects of L-NOARG on vasoconstrictor responses to NA in HCG-treated 115
rabbits.
61 Effect of L-NOARG on vasodilator responses to carbachol and SNP in HCG- 117
treated rabbits.
62 Vasoconstrictor responses to NA and oxymetazoline in oestrogen-treated 119
rabbits.
63 Effects of L-NOARG on vasoconstrictor responses to NA in oestrogen-treated 120
rabbits.
64 Effects of 17-fi-oestradiol on NA-induced vasoconstriction. 122
65 Vasoconstrictor responses to NA and oxymetazoline in pregnant rabbits. 123
66 Vasoconstrictor response to histamine in control and pregnant rabbits. 124
67 Effects of L-NOARG on vasoconstrictor responses to NA and oxymetazoline 125
in pregnant rabbits.
68 Effects of yohimbine on NA-induced vasoconstriction in pregnant rabbits.
x i i i
69 Effects of prazosin on NA-induced vasoconstriction in pregnant rabbits. 127
70 Effect of CEC and SZL-49 on NA-induced vasoconstriction in pregnant 128
rabbits.
71 A typical trace of carbachol-induced vasodilation before and after treatment 130
with L-NOARG in pregnant rabbits.















Drugs used in the identification of a-adrenoceptors. 8
Classification of a r adrenoceptors 11
Classification of a 2-adrenoceptors 15
Isoforms of nitric oxide synthase. 26:
ED50 and Emax values for some adrenergic agonists. 76
Antagonist poetencies of prazosin against several agonists. 83
Antagonist potencies of WB-4101 against several agonists. ®
Basal perfusion pressure in control and treated groups of rabbits. 110
ED50 values for several agonists in different groups of rabbits.  ^^
Maximal increases in perfusion pressure produced by several agonists in 114 
different groups of rabbits.
ED50 values and maximal reduction in perfusion pressures for carbachol and 118 




1.1 Ovarian vascular bed
The ovary is one of the most highly vascularized organs of the body. Both ovaries are 
supported by a mesentery called the mesovarium. An additional mesentery, the ovarian 
ligament attaches each ovary to the lateral edge of the uterus (Fig.l) (Wingerd, 1985). 
Each ovary is divisible into a central medulla which comes to the surface along the 
thin edge of the ovary; and a peripheral cortex, which invests all other portions of the 
medulla. In the ovary of the young adult rabbit there is very little if any interstitial 
tissue, and the mature follicles, with their bases bordering the medulla, occupy the 
entire thickness of the enveloping cortical tissue. The medulla is made up of loose 
connective (stromal) and interstitial tissue which support the major arteries, veins and 
lymphatics (Burr & Davies, 1951).
1.1.1 Blood supply to the ovary
Blood supply to the ovaries is through the ovarian arteries from the anterolateral 
aspects of the aorta. Each ovarian artery arises from the dorsal aorta about 3cm 
posterior the renal artery. About midway between the dorsal aorta and the ovary each 
ovarian artery gives rise to a branch which supplies the oviduct and the uterus (Burr & 
Davies, 1951). Before entering the ovary, the artery is often thrown into one or more 
loose coils. Intra-ovarian branches of the ovarian artery are spiralled. The spiral 
arteries control blood flow so that the cortex receives a uniform supply of blood under 
reduced pressure. It has also been hypothesized that this spiralling may facilitate 
extension of the artery toaccoomodate the growth of the ovary during the follicular 
phase of the cycle and during formation of the corpus luteum following ovulation 
(Reynolds, 1950).
1.1.2 Innervation of the ovary
Sympathetic nerves supplying the reproductive tract originate not only from pre- and 
paravertebral ganglia, but also from adrenergic ganglionic formations located in the 
immediate vicinity of the effector organs (short adrenergic nerves). The short 
adrenergic neurons have been found to differ functionally from ordinary long neurons 
(Euler & Lishajko, 1966), especially in relation to their sensitivity to reserpine and 6- 
OHDA. It is quite possible that this specific pattern of adrenergic innervation has a 
special physiologic significance in the female reproductive tract (Fig.2).
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Fig.l The reproductive system of the female rabbit, (modified from Wingerd, 1985)
Fig. 2 Anatomy and distribution of the major sympathetic nerve supply to the human 
ovary. The superior mesenteric (a) and celiac (b) ganglia connect with the aortico-renal 
plexus (c), from which the ovarian plexus (d) arises to run along the ovarian vessels to 
the ovary (e). The corresponding half of the uterus is indicated (f). (cited from Owman 
etal., 1991)
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The density of adrenergic innervation agrees well with the amount of NA contained in 
the ovaries (Rosengen & Sjoberg, 1967). Noradrenaline is present in the ovaries of 
many mammalian species. There is considerable species variation in ovarian 
noradrenaline concentration, ranging from 0.2 pg/g in the rat to 4.2 pg/g in the cat 
(Mohsin & Pennefather, 1979). Ovarian noradrenaline is not significantly altered 
during pregnancy, after treatment with 17-B-oestradiol and or progesterone, or with 
HCG, in contrast to the marked alterations that can be induced in short adrenergic 
neurons supplying the uterus, vagina and oviduct under these conditions (Owman et 
al., 1979).
1.13 Adrenergic regulation of ovarian function
One of the main functions of the ovary is the release of matured ova which then pass 
along the fallopian tube, where they are fertilized, to the uterus where implantation 
takes place. Anatomical and physiological studies have suggested that ovarian smooth 
muscle nerves may function to facilitate the process of ovulation (Owman et al., 1979). 
Pharmacological experiments have indicated the presence of a - and B- adrenergic 
receptors in the follicular wall which mediate contractile and dilator responses (Walles 
et al., 1975), suggesting that the neuromuscular complex in the theca externa may be 
involved in the ovulatory process.
A role of ovarian innervation to modulate steroidogenesis was suggested on basis of 
electron microscopic observations and fluorescent histochemical studies (Burden, 
1972). In rat and guinea pig ovaries the interstitial cells receive a dense adrenergic 
innervation. These cells are believed to secrete androgen and oestrogens. Their 
particular anatomical location suggests that a process of neuroendocrine transduction 
(Wurtman, 1973) may be possible within the ovary. Lawrence and Burden (1976) 
observed that the density of adrenergic innervation of interstitial cells of rat ovary 
increases during pregnancy, supporting the possibility of an autonomic influence on 
steroidogenesis. Since adrenergic fibres do not penetrate into the granulosa layer of 
the follicles, or into corpora lutea, it seems unlikely that they directly influence steroid 
production by the latter structures (Mohsin and Pennefather, 1979).
Adrenergic antagonists, such as phenoxybenzamine, and denervation of the ovary have 
been shown to modify ovarian function (Bahr et al., 1974).
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1.1.4 Ovulation
Immediately after the onset of menstruation, and by a mechanism still unknown, one 
follicle is selected for further development. This follicle, under the influence of FSH 
begins to differentiate rapidly becoming the dominant follicle. At the same time, the 
other follicles undergo atresia. There is increased vascularization of the dominant 
follicle which allows for a more efficient delivery of cholesterol and circulating 
gonadotrophins. The dominant follicle is the main source of circulating oestradiol. At 
about mid-cycle, the elevated levels of oestradiol exert a positive feed back effect on 
the secretion of LH and FSH. The LH surge leads to a series of coordinated 
biochemical and morphological events including activation of proteolytic enzymes, 
granulosa cell differentiation, release of histamine, prostaglandins and other hormones 
(Ffpades & Tanner, 1995). The ultimate result is follicular rupture and ovulation. The 
physiological role of the midcycle FSH surge is not clear, it is however not essential 
for ovulation as ovulation can be induced, before the midcycle surge of endogenous 
gonadotrophins, by injecting LH or HCG (Trades & Tanner, 1995).
Most female mammals exhibit a definite period of sexual receptivity near the time of 
ovulation, referred to aso&strus (heat). This is the only period when copulation can take 
place, ensuring that the female is mated at the time of ovulation (Rhoades & Tanner, 
1995). On the other hand, female rabbits and cats are in a state of persistant oestrus 
and are sexually receptive to males. These are the reflex ovulators. In these animals, 
ovulation takes place within a definite period after mating (Hadley, 1984). In female 
rabbits, ovulation usually takes place 10-12hr after mating or HCG injection 
(Virutamasen et al., 1971; Lambertsen et al., 1976).
1.1.4.1 Vascular dynamics during ovulation
At ovulation, surge of LH causes a conspicuous change in the ovarian vasculature. 
Within a few minutes after gonadotropin stimulation there is a significant increase in 
ovarian blood flow (Wurtman, 1964; Lee & Novy, 1978) resulting from an LH- 
mediated release of vasodilator substances such as histamine, bradykinin and 
prostaglandins. The elevation in ovarian blood flow lasts for at least 9 hours, with a 
peak at about 4 hours after gonadotropin stimulation (Blasco et al., 1975). This 
increase in circulation is associated with the hyperaemic condition that develops in the 
dominant follicles to LH (Burr & Davis, 1951; Espey, 1974). Along with
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vasodilatation, there is an increase in vascular permeability in the follicles (Zacchariae, 
1958; Espey 1978). These vascular changes cause the follicle to become oedematous, 
a condition which persists until the time of follicular rupture (Bjersing & Cajander, 
1974; Chemey et al., 1975). Thus LH induces ovarian hyperemia, vasodilatation, 
oedema and extravasation of blood in ovulatory follicles (Espey, 1980).
The two phenomenon most often observed in connection with ovulation are the 
engorgement of the ovarian blood vessels and the distension of the follicles due to the 
accumulation of fluid in them (Burr & Davies, 1951).
1.2 Classification of alpha-adrenoceptors
1.2.1 Concept of a t- and a 2-adrenoceptors
Brown and Gillespie (1957) observed that a-adrenoceptor antagonists increased the 
overflow of noradrenaline from the perfused cat nictating membrane evoked by 
sympathetic nerve stimulation. This was thought to be due to the presence of a- 
adrenoceptors on the nerve terminals, blockade of which was responsible for the 
increased noradrenaline overflow (Langer et al., 1971; Starke et al., 1971b). It was 
proposed that these receptors exist predominantly pre-synaptically, constituting a 
negative feed back mechanism to regulate neurotransmitter release. This is in contrast 
to post-junctionally located a-adrenoceptors which mediate end-organ responses to 
noradrenaline. Because the receptors differ in their sensitivities to a-adrenergic 
agonists and antagonists, it was suggested that these adrenoceptors should not be 
characterized based on their anatomical distribution but rather on their functional 
activities (Berthelsen & Pettinger, 1977). On this basis, it was concluded that a p  
adrenoceptors were excitatory while a 2-adrenoceptors were inhibitory. These receptors 
were designated aj-(post-junctional) and a 2-(pre-junctional) adrenoceptors. Later 
studies have shown that a 2-adrenoceptors located post-junctionally, could also 
mediate excitatory responses. Drew and Whiting (1979) observed that NA-induced 
vasoconstrictor responses in rats and cats, were inhibited by both selective otp and a 2- 
adrenoceptor antagonists. Therefore, the universally accepted method of classification, 
is that based solely on the relative affinities of highly selective antagonists, ctj- 
Adrenoceptors were found to have high affinity for agonists such as phenylephrine, 
methoxamine and 6-fluoronorepinephrine, while a 2-adrenoceptors have higher
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selectivity for drugs such as clonidine and UK 14,304. The subdivision of a- 
adrenoceptors into a r and a 2-adrenoceptor subtypes was further substantiated by the 
development of selective antagonists for each subtype, a  j-Adrenoceptors were found 
to be antagonized selectively by prazosin, WB-4101, corynathine, phenoxybenzamine, 
benoxathian and benextramine; and a 2-adrenoceptors being selectively inhibited by 
drugs like rauwolscine, yohimbine and idazoxan (Table 1) (Ruffolo, 1990).
1.2.2 Subclassification of a r adrenoceptors
a r Adrenoceptors are by definition potently antagonized by prazosin and show low 
affinity for selective a 2-adrenoceptor antagonists such as yohimbine or rauwolscine 
(Bylund et al., 1994). However, a survey of the literature reveals a remarkable 
variation in the potency of prazosin in antagonizing a  v-adrenoceptor mediated 
effects (Agrawal et al., 1984; Medgett & Langer, 1984; Flavahan & Vanhoutte, 1986).
Such variations spanning over approximately two orders of magnitude (i. e. 100 fold 
variation) would possibly indicate heterogeneity of a  j-adrenoceptors. In a study on 
the rat caudal artery preparation, Medgett & Langer (1984) observed that prazosin 
was more effective against methoxamine (KB=0.2nM) than against NA (KB=1.3nM). 
They also observed that corynanthine, another selective a r adrenoceptor antagonist 
was equipotent against methoxamine and NA. It was therefore, suggested that 
methoxamine selectively activated the a  t-adrenoceptor sub-type having high affinity 
for prazosin. NA presumably stimulated both high and low affinity prazosin binding 
sites. Hoick et al (1983) also noted that prazosin was more potent against clonidine- 
than methoxamine-induced contractions of the rabbit pulmonary artery. The variation 
in prazosin affinity is not only observed between species, it could also occur within the 
same species. For example, the pKg value for prazosin against NA in the rat aorta 
reported in the literature varies from 9.5-10.6 whereas in the tail artery, the pKB is less 
than 9 (Agrawal et al., 1984). It also occurs between different agonists on the same 
tissue.
1.2.2.1 Concept of a 1H-, a 1L-and a 1N-adrenoceptor subtypes 
Based on the various affinities of prazosin and yohimbine in the literature, Flavahan 
and Vanhoutte (1986) proposed a subdivision of a {-adrenoceptors into a 1H (high 
affinity for prazosin and yohimbine) and a 1L (low affinity for prazosin and 
yohimbine). This type of subdivision would however notawmmodate the rat tail
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Table 1 Adrenoceptor agonists and antagonists commonly used in the subclassification 
of a r  and a 2-adrenoceptors. (cited from Ruffolo et al., 1991)
«i-Adrenoceptor











artery. Like other rat vessels, the potency of yohimbine against noradrenaline was 
high in the tail artery (KB=100 nM). However, prazosin was much less potent (KB < 
InM) as compared with other tissues of the rat resulting in a lower prazosin/yohimbine 
ratio in this preparation.
The functional classification of a!-adrenoceptors into a 1H- and a 1L-subtypes by 
Flavahan and Vanhoutte (1986), has recently been modified to include a third group, 
a 1N, which have a relatively low affinity for prazosin and a higher than expected 
affinity for yohimbine (Muramatsu et al., 1990).
1.2.2.2 a 1A-, a 1B- and a 1D-adrenoceptor subtypes
Morrow et al (1985) observed that, in the rat brain, WB-4101 and phentolamine 
produced a biphasic displacement of [ H]-prazosin consistent with a two-receptor 
system. This was later confirmed by Morrow and Creese (1986) using rat cerebral 
cortex, who designated these sites as a 1A-(high affinity for WB-4101) and aIB- (low 
affinity for WB-4101) adrenoceptors. Similar observations were made in different 
parts of the rat brain by Han et al (1987 ) who also showed that these receptor subtypes 
could be differentially affected by drugs. Thus WB-4101 was more effective against 
a 1A-(about 20 fold more potent) than a 1B-adrenoceptors. On the other hand, CEC, 
a reactive analogue of clonidine (LeClerk et al., 1980), inactivated a 1B- but not a1A- 
adrenoceptor subtype. The site inactivated by CEC in the rat brain corresponded to the 
low affinity WB-4101 binding site, thus indicating an inverse sensitivity of a 1A- and 
a 1B-adrenoceptor subtypes to WB-4101 and CEC. Other compounds which 
differentially interact with the receptor subtypes include phentolamine, 5-methyl- 
urapidil, (+)-niguldipine, benoxathian and ipsapirone (a 1A > ct|B) (Morrow & Creese, 
1986; Han et al., 1987; Boer et al., 1989; Gross et al., 1988; Eltze et al.,1991), or 
spiperone (a 1B > a 1A) (Michel et al., 1989a). The existence of a 1A- and a 1B- 
adrenoceptor subtypes is also supported by data from cloning studies (Schwinn et al., 
1990; Lomasney et al., 1990 & Cotecchia et al., 1990). The a 1B-adrenoceptor subtype 
was the first of the a  j-adrenoceptor family to be cloned. This clone was isolated from 
the hamster vas deferens and encoded for a protein having a sequence consistent with 
a G-protein-coupled receptor (Cotecchia et al., 1988). Expression of this cDNA 
resulted in a protein with radioligand-binding properties consistent with an a 1B- 
adrenoceptor, with a high affinity for prazosin and a low affinity for phentolamine, 5-
9
methylurapidil and yohimbine. Functionally, a 1A-adrenoceptors predominate in the 
vas deferens (Han et al.,1990) and intrarenal vascular bed of the rat (Clarke et al., 
1990; Eltze et al., 1991; Munawar & Johns, 1991; Elhawaiy et al., 1992).
Lomasney et al., (1991) have shown that screening of a rat brain libraiy with a cDNA 
probe prepared from the hamster a 1B-adrenoceptor revealed a cDNA clone for another 
a  j-adrenoceptor subtype. The amino acid sequence of the protein expressed by this 
clone is consistent with a seven transmembrane spanning, G-protein linked receptor. 
The tissue distribution of mRNA transcribed by this clone suggested a similar 
distribution to that of the a 1A-subtype, and the expressed receptor had a high affinity 
for WB 4101. This led to the conclusion that this clone represented the 
pharmacologically defined a 1A-adrenoceptor (Lomasney et al., 1991). However, Perez 
et al., (1991), studying an almost identical clone also isolated from rat brain, found low 
affinity for the more selective a IA-adrenoceptor antagonists, 5-methylurapidil and (+)- 
niguldipine. They concluded that a clone for a novel a  r adrenoceptor subtype had 
been isolated and denoted it as a 1D. The clones isolated by Lomasney et al. (1991) and 
Perez et al. (1991) encode for 560 amino acid proteins differing in sequence at only 
two sites (99.8% amino acid identity), therefore, it seems likely that they represent the 
same subtype. This receptor subtype was designated a  j ^ -adrenoceptor. Since the 
expressed cDNA has pharmacological properties substantially different from those 
found for the a IA-adrenoceptor in native tissues, this recombinant receptor should be 
referred to as the a 1A/D-adrenoceptor until these discrepancies can be explained and a 
native receptor having similar pharmacology identified (Bylund et al., 1994). The 
human homolog of this a r adrenoceptor subtype has been cloned recently (Forray et 
al, 1993) (Table 2).
1.2.23 a lc-adrenoceptors
An additional cDNA clone has been found based on homology screening of a bovine 
cerebral cortex with a probe derived from the hamster a IB-adrenoceptor. The protein 
expressed by this clone was found to be distinct from the a 1B-adrenoceptor, with 65% 
amino acid homology in the membrane-spanning domains. The pharmacological 
profile was also distinct from either the a jB- or a 1A/D-adrenoceptors, with a relatively 
high affinity for 5-methylurapidil and a high affinity for WB-4101. In view of its 
distinct pharmacological profile, this receptor was designated the a lc-adrenoceptor.
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Table 2 A modified putative classification scheme for a!-adrenoceptors, (n.d., not 
determined; cited from Ford et al., 1994)
a d r e n o c e p t o r  
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The affinities of a series of competitive antagonists for displacement of [3H] prazosin 
from expressed a lc-adrenoceptors correlates very well with their affinities for binding 
sites in native tissues that are known to express a 1A-adrenoceptors (Testa et al., 1995; 
Ford et al., 1994; Saussy et al., 1994; Langer et al.,1994). It could therefore be that the 
recombinant a lc-adrenoceptor actually represents the native a IA-adrenoceptor (Ford et 
al., 1994). Further studies have shown that, like native a 1A-adrenoceptors, 
recombinant rat (Laz et al., 1994) or human (Forray et al., 1994; Schwinn et al., 1991) 
a lc-adrenoceptor is relatively resistant to alkylation by CEC. Recently, mRNA for the 
a lc-adrenoceptor has been identified in human prostate (Price et al., 1993), and the 
contractile response induced by a  v-adrenoceptor activation in this tissue appears to be 
mediated by an adrenoceptor having pharmacological characteristics corresponding to 
those of the expressed recombinant a lc-adrenoceptor (Marshal et al., 1992 & Forray 
et al., 1993). Recent data suggest that the a lc clone, at least its rat homolog, may 
correspond to the pharmacologically defined a 1A-adrenoceptor (Laz et al., 1993). 
Comparison of the recombinant rat a lc-receptor to the other two recombinant rat a r  
adrenoceptors, revealed that the former has significantly lower sensitivity to 
irreversible inactivation by CEC and relative antagonist affinities correlating well with 
that of the native a 1A-adrenoceptor (Laz et al., 1993).
1.2.2.4 Atypical aj-adrenoceptors
The atypical a  j-adrenoceptor described by Abel et al., (1995) has a number of 
similarities to the a 1L-adrenoceptor described by Muramatsu and co-workers (1990; 
1991). The a 1L-adrenoceptor is found in vascular smooth muscle (e.g. thoracic aorta) 
of the guinea-pig and is insensitive to inactivation by CEC. a 1L-adrenoceptor has a 
low affinity for prazosin ( > InM) and a relatively low affinity for WB-4101 (1-10 
nM). The atypical a  j-adrenoceptor in the vascular smooth muscle of the guinea-pig 
mucosa, ileum and in the rat parotid gland is also insensitive to inactivation by CEC. 
In all three tissues, the atypical receptor has a low affinity (1-4 nM) for prazosin and 
low affinity (5-18 nM) for WB-4101. These similarities in pharmacological 
characteristics and the identification of both a 1L- and the atypical a!-adrenoceptor in 
vascular tissue from the guinea-pig suggest that these two receptor types may actually 
represent the same a r adrenoceptor sub-type (Abel et al., 1995). This is the population 
of a r adrenoceptors that displays a relatively low affinity for prazosin and, therefore,
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has been largely ignored in many radioligand binding studies. These receptors are 
termed a 1L-adrenoceptors. Whether novel cDNAs exist for this adrenoceptor sub­
family or whether they represent variants of the cloned ctj-adrenoceptors, remains to 
be determined (Ford et al., 1994).
1.23 Subclassification of a2-adrenoceptors
The presence of post-junctional, vascular a 2-adrenoceptors has been demonstrated, 
primarily by using in vivo preparations such as the pithed rat (Drew & Whiting, 1979; 
Timmermans et al., 1979; Ruffolo et al., 1983). These receptors have been also 
studied in vitro using isolated cutaneous veins from the dog (Flavahan & Vanhoutte,
1986), rabbit (Schumann & Lues, 1983), and human (Docherty & Hyland, 1984). All 
known a 2-adrenoceptor sub-types are activated by NA and adrenaline, and there is no 
evidence that these physiological catecholamines show significant selectivity between 
any of the known a 2-adrenoceptor sub-types. All subtypes can be blocked by 
yohimbine and rauwolscine (receptor dissocation constant < 40 nM) and labelled with 
[3H] analogues of these antagonists, although the affinity can vary substantially 
between sub-types. The earliest subdivision of a 2-adrenoceptors was based on species 
heterogeneity. For example, Waterfall et al. (1985) reported that the affinities of 
rauwolscine, yohimbine and a series of substituted benzoquinoxolazines were roughly 
equivalent at pre-junctional a 2-adrenoceptors in the rat vas deferens, while the 
affinities of yohimbine and rauwolscine were approximately 100-fold greater than 
those for the benzoquinoxolazines for the pre-junctional a 2-adrenoceptor in the rabbit 
vas deferens. However, careful analysis of the ability of prazosin to inhibit [3H]- 
yohimbine binding to various regions of both rat (Bylund, 1985), and human (Petrash 
& Bylund, 1986) brain, have revealed discrete regions of heterogeneity within each 
species. In some regions, the inhibition was characterized by prazosin competing with 
low affinity for only one site, and in others it was characterized by prazosin competing 
with two sites, one with a low affinity, identical to that seen in the human platelet, and 
the other with high affinity identical to that seen in the neonatal rat lung. Bylund 
(1985) proposed a sub-classification of a 2-adrenoceptors based on the relative potency 
of prazosin, with the receptor having the low affinity for prazosin, typified by the 
human platelet a 2-adrenoceptor, termed a ^ ,  and the receptor having a relatively 
higher affinity for prazosin, typified by the neonatal rat lung a 2-adrenoceptor, termed
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a 2B. More recent studies have confirmed this sub-classification of a 2-adrenoceptors 
and have identified other tissues that possess one or the other of these a 2-adrenoceptor 
subtypes (Bylund et al., 1988). Moreover, several ligands have been shown to have 
some degree of selectivity for one or the other of these a 2-adrenoceptor subtypes. 
Benoxathian, oxymetazoline and WB 4101 are relatively selective for a 2A- 
adrenoceptors, while chlorpromazine, imiloxan and prazosin are relatively selective for 
a 2B-adrenoceptors (Michel et al., 1989b). Importantly, functional studies of the 
inhibition of a 2-adrenoceptor-mediated attenuation of cAMP production with sub-type 
selective antagonists in HT29 and NG108-15 cells have confirmed the existence and 
definition of the a 2A- and a 2B-adrenoceptor subt-ypes (Bylund & Ray-Prenger, 1989). 
A third a 2-adrenoceptor subtype, a 2C-adrenoceptor, has been proposed. This receptor 
was identified in opossum kidney-derived cell line (OK cells) (Murphy and Bylund,
1988), which has characteristics similar to that of a 2B-adrenoceptors (a relatively high 
affinity for prazosin), but the ratio of affinities of prazosin and yohimbine is 
intermediate between a 2A- and a 2B-adrenoceptors (Table 3) (Bylund & Ray-Prenger,
1989). By correlation of antagonist affinity for inhibition of [ H]-rauwolscine binding 
in different cell and tissue preparations, two additional a 2-adrenoceptor subtypes have 
been proposed, designated a 2C and a 2D (Bylund et al., 1994).
Results obtained in molecular biology studies have confirmed the existence of a 2- 
adrenoceptor subtypes. Several clear correlations exist between the a 2-adrenoceptor 
sub-types identified in native tissues and cell lines and the receptor proteins expressed 
from cDNA clones. These correlations are supported by hybridization of the a 2- 
adrenoceptor clones with tissues known to contain a particular a 2-adrenoceptor 
subtype (Bylund et al., 1992; Lomasney et al., 1990; Harrison et al., 1991).
1.2.3.1 Pre- versus post-junctional a2-adrenoceptors
The rank order of potency of a series of a 2-adrenoceptor antagonists appears to be 
similar at pre- and post-junctional a 2-adrenoceptors in vivo (Berridge et al., 1984; 
Docherty & Hyland, 1985). Determination of receptor dissociation constants for 
standard a 2-adrenoceptor antagonists in isolated preparations measuring pre- and post­
junctional a 2-adrenoceptor affinity likewise does not suggest a pharmacologic 
difference in these two receptors (Hieble et al., 1986a). Such antagonists include 
imidazolines (e.g. phentolamine), 3-benzazepines (SK&F 86466), yohimbine alkaloids
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(rauwolscine and yohimbine) and benzodioxanes (piperoxan). Modification of the 3- 
benzazepine structure yielded compounds such as SK&F 104078 which exibited 
different affinities for pre- and post-junctional a 2-adrenoceptors (Hieble et al., 1988; 
Ruffolo et al., 1987; Hieble etal., 1986b). Thus SK&F 104078 antagonized 
UK14,304-induced contractions of the canine saphenous vein without affecting the 
twitch-inhibiting effect of a-methylnoradrenaline in the guinea pig ileum (Hieble et 
al., 1988) and vas deferens. Further studies revealed that SK&F 104078 could 
differentiate between sub-types of pre-junctional a 2-adrenoceptors. In the rat vas 
deferens, SK&F 104078 antagonized twitch-inhibiting effect of clonidine but not 
UK14,304 or B-HT 920 (Oriowo et al., 1991). The potency of SK&F 104078 in 
inhibiting clonidine was similar to its potency at post-junctional a 2-adrenoceptors. It 
was concluded that there is a heterogenous population of pre-junctional a 2- 
adrenoceptors in the rat vas deferens with one population identical to the post­
junctional a 2-adrenoceptors. On the other hand, guinea-pig atrium contains a 
homogenous population of SK&F 104078-insensitive prejunctional a 2-adrenoceptors.
13 Signal transduction mechanisms
Calcium plays a pivotal role as an intracellular second messenger. Although cells 
contain a lot of Ca2+, most of it is not free as the Ca2+ is either bound by a variety of 
proteins or sequestered by organelles such as the mitochondria and endoplasmic 
reticulum (Berridge, 1984). Furthermore, there are several pumps and exchange 
systems which remove free Ca2+ from the cytoplasm if its concentration begins to rise.
2+ 7All these factors maintain the resting [Ca ]\ at very low levels (<10" M) (Miller, 
1987). During excitation, the transient increases in [Ca2+]i, which act as important 
intracellular signals, can be initiated in two ways. Firstly, calcium can be released 
from intracellular storage sites associated with the endoplasmic reticulum. Secondly,
2+ 2+the [Ca ]j could also rise due to an increase in the Ca permeability of the plasma
2+
membrane. This is achieved by the opening of Ca channels by the action of some 
agonists on receptors or in response to changes in membrane potential (Bolton 1979). 
Earlier studies have consistently shown that a 2-adrenoceptor mediated 
vasoconstriction, in vivo or in vitro was highly dependent on an influx of extracellular 
Ca . Thus the response was virtually abolished in a Ca -free medium (Matthews et
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al., 1984; Cooke et al., 1985) and significantly reduced by organic and inorganic Ca2+ 
channel inhibitors (van Meel et al., 1981; Matthews et al., 1984). These observations 
were supported by the observation that B-HT 920, an a 2-adrenoceptor agonist 
promoted influx of 45Ca2+ which was inhibited by nifedipine and verapamil (Matthews 
et al., 1984). The situation was not as straight forward following aj-adrenoceptor 
activation. Pressor responses in vivo mediated by post-junctional vascular a r  
adrenoceptors were found to be resistant to inhibition by calcium channel antagonists 
(van Meel et al., 1981 & Cavero et al., 1983), suggesting that, unlike a 2- 
adrenoceptors, a  j-adrenoceptors may not rely heavily upon extracellular calcium to 
produce vasoconstriction. However, not all selective <Xi-adrenoceptor agonists produce 
vasoconstriction in vivo that is resistant to inhibition by calcium channel blockers. For 
example, Sgd 101/75 and (-)-dobutamine all produce a  {-adrenoceptor-mediated 
pressor responses in pithed rats that are inhibited by calcium channel blockers (Ruffolo 
et al., 1984). Therefore, it would appear that some a r adrenoceptor agonists can 
produce vasoconstriction via both influx of extracellular calcium and release of 
intracellular calcium. Further analysis has revealed that partial cq-adrenegic agonists 
produce vasoconstrictions that are attenuated by Ca channel inhibitors while similar 
responses induced by full agonists are insensitive to calcium channel inhibitors. It was 
therefore suggested that agonist efficacy determines whether a r adrenoceptor
2+ j .
mediated vasoconstriction is dependent on extra- or intracellular Ca . This concept is 
also supported by results obtained in functional studies. For example, in the pithed rat 
preparation, B-HT 933 and cirazoline induced dose-dependent pressor effects and 
relative to cirazoline, B-HT 933 was a partial agonist Diltiazem significantly inhibited 
B-HT 933, but not cirazoline-induced pressor responses. After treatment with 
phenoxybenzamine to reduce efficacy, the sensitivity of cirazoline-induced pressor
responses to diltiazem was significantly enhanced (Ruffolo et al., 1984). The
2+dependence of a  j-adrenergic agonists on extra- and intracellular Ca is supported by 
results obtained in studies in which Ca flux was studied using inorganic calcium 
inhibitors (Deth & Lynch, 1981). In rabbit aorta, a r adrenoceptor activation produces 
an influx of extracellular calcium (Cauvin et al., 1982). Moreover, even a p  
adrenoceptor agonists that are relatively insensitive to inhibition by calcium channel 
antagonists (e.g. cirazoline), produce a significant influx of extracellular calcium of a
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magnitude that is greater than that produced by agonists (e.g. St 587) that show a high 
degree of sensitivity to inhibition by calcium channel antagonists (Chiu et al., 1986). 
In addition, studies of the efflux of Ca2+ have shown that a r adrenoceptor agonists 
also induce a release of calcium from intracellular stores (Deth and Lynch, 1981 &
Cauvin et al., 1982), although only those agonists with high intrinsic efficacies
2+produced a significant release of intracellular Ca (Chiu et al., 1986). This would 
perhaps explain why, in many vascular smooth muscle preparations, a  j-adrenoceptor- 
mediated contraction is made up of two components, an initial fast (phasic) component 
and a secondary (tonic) phase. These phases, according to efflux studies utilize 
different Ca2+ pools. It has been suggested that the initial fast phase of NA-induced 
tension development depends to a large extent on Ca2+ release; while, the tonic phase 
is dependent on Ca2+ entry (Van Breemen et al., 1986). Based on these observations, 
the following hypothesis was proposed; upon a!-adrenoceptor activation, calcium 
from a small labile intracellular store on the inner surface of the plasma membrane is 
released. This calcium does not activate smooth muscle contraction directly, but rather 
triggers the release of calcium from the sarcoplasmic reticulum. Simultaneously, 
calcium bound on the outer surface of the plasma membrane is released and enters the 
cell through receptor-operated calcium channels. These two processes, which are 
responsible for the early phasic component of contraction, are followed by an influx of 
calcium from the free extracellular calcium pool that produces the secondary tonic 
contraction (Leijten et al., 1985).
13.1 ocj-Adrenoceptor subtypes and Ca2* utilization
 ^I
The differential sensitivity of full and partial agonists to Ca channel inhibitors could 
suggest that different a!-adrenoceptor subtypes mediate the response to full and partial
agonists. With this assumption, the enhanced sensitivity of a vasoconstrictor effect of
2+a full agonist to a Ca channel inhibitor following treatment with phenoxybenzamine 
was interpreted to suggest that phenoxybenzamine inactivated only the subtype 
coupled to intracellular Ca2+ release (Chiu et al., 1986). However, Oriowo et 
al.(1992) have shown, using receptor protection studies that in the rat aorta, the same 
a r adrenoceptor subtype could be coupled to more than one source of activator Ca2+ 
(i.e. to extra- and intracellular Ca2*). The fact that NA induced contractions of the rat
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aorta were mediated only by CEC sensitive a r adrenoceptors (Oriowo & Bevan, 1990; 
Oriowo & Ruffolo, 1992) would support this hypothesis.
Sub-types of a r adrenoceptors have recently been identified using pharmacological 
(ligand binding and functional studies) and molecular biological techniques (see 
section 1.2.2). Thus, presently, three subtypes, a 1A-, a 1B- and a 1D-subtypes exist
(Watson & Girdlestone, 1996). It was earlier suggested that a 1A- and a 1B-subtypes
2+were coupled to extracellular and intracellular Ca respectively (Han et al., 1987; 
Minneman, 1988). This was based on the fact that a 1A-mediated NA-induced
contractions of the rat vas deferens (Han et al., 1987) were abolished by nifedipine
2+indicating total dependence on influx of extracellular Ca . In the same study ( Han et 
al., 1987), NA-induced contractions of the splenic strip (a m-mediated) were not
significantly affected by nifedipine. However, later studies have shown that both a 1A-
2+and a 1B-adrenoceptors could mobilize Ca from extracellular and intracellular 
sources. This has been observed in guinea-pig hepatocytes (Garcia-Sainz et al., 1992), 
and rat brain and renal cortex (Michel et al., 1993; Han et al., 1990; Wilson & 
Minneman, 1990).
In most systems, calcium translocation produced by agonist interaction with a p  
adrenoceptors is believed to be secondary to enhanced Ptdlns turnover, due to 
activation of PLC (Fig. 3) (Michell, 1979). There is a correlation between a r  
adrenoceptor-mediated contraction of rabbit aorta and the increase in Ptdlns turnover 
(Villalobos et al., 1982). This would tend to suggest a causative link between a p  
adrenoceptor-mediated activation of PLC leading to hydrolysis of Ptdlns and 
subsequent smooth muscle contraction. It was later observed that cq-adrenoceptor- 
stimulation of phospholipid turnover was the result of the hydrolysis of phospho- 
inositides (Berridge, 1983). The products of this hydrolysis, DAG and Ins(l,4,5)P3, 
have been proposed to be the second messengers responsible for transduction of the 
aradrenoceptor signal (Berridge, 1984). Ins(l,4,5)P3 has been shown to release 
calcium ions from the endoplasmic reticulum in liver (Burgess et al., 1984; Joseph et 
al., 1984), whereas DAG activates cytosolic PKC (Kishimoto et al., 1980), which 
under certain conditions, may induce slowly developing vascular smooth muscle 
contraction (Danthuluri and Deth, 1984; Rasmussen et al., 1984) possibly via an 
interaction with MLCK (Nishikawa et al., 1984). Phosphorylation of DAG, yield PA,
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Fig. 3 Generation and action of inositol (l,4,5)-triphosphate. (cited from Boeynaems 
& Pirotton, 1994)
a calcium ionophore (Tyson et al., 1976), which causes calcium-dependent smooth 
muscle contraction (Salmon and Honeyman, 1980). There is the possibility that PA 
may also be involved in the transduction of a r adrenoceptor signal (Ruffolo and 
Hieble, 1994).
PKC is a phospholipid- and Ca2+-dependent enzyme which has been shown to 
phosphorylate a number of substrates including myosin (Adelstein & Sellers, 1987). 
PKC plays a role in various biological responses including neurotransmitter release 
and neurotransmitter-induced contraction of vascular smooth muscle (Nishizuka, 
1986; Rasmussen et al., 1987; Lee & Sverson, 1994). PKC is activated by DAG and is 
distributed in sympathetic nerves and other tissues (Malhotra et al., 1988; Kuo et al., 
1980). Several isoforms of PKC have been identified in vascular smooth muscle (Liou 
& Morgan, 1994). In vascular smooth muscle, phorbol esters which activate PKC, 
increases Ca2+ influx (Sperti & Colucci, 1987; Jiang & Morgan, 1987) and have been 
reported to increase calcium channel currents in rat portal vein cells (Loirand et al.,
1990) and rabbit saphenous artery cells (Oike et al., 1992). The ability of 
antiphosphoinositide antibodies to inhibit NA-induced increases in calcium channel 
currents in rat portal vein cells is consistent with this proposed role for PKC (Loirand 
etal., 1992).
The principal kinase involved in smooth muscle contraction is generally accepted to be 
MLCK. After binding the Ca2+-CaM complex, MLCK phosphorylates the 20kDa light 
chain of myosin thus initiating smooth muscle contraction (Kamm & Stull, 1985). 
Although activation of MLCK is necessary for contractile force generation, activation 
of PKC may be required for force maintenance (Rasmussen et al., 1987). The 
activation of PKC is known to induce slowly developing but sustained cellular 
responses (Nishizuka, 1986). Jiang and Morgan (1987) have suggested that the 
activation of PKC increases the sensitivity of contractile elements to cytosolic calcium. 
Other structural and regulatory proteins of smooth muscle have been reported to 
become phosphorylated by PKC after phosphorylation of MLCK. Maintenance of 
these proteins in the phosphorylated state during the sustained phase of smooth muscle 
contraction after both dephosphorylation of myosin light chain and the return of 
intracellular Ca2+ to near basal level has been explained to suggest a role for PKC in 
the tonic phase of smooth muscle contraction (Rasmussen et al., 1987).
Pharmacological studies seem supportive of some role for PKC in smooth muscle 
contraction. Activators of PKC, such as PMA and some other phorbol esters, induced 
slow and sustained contractions of smooth muscle (Rasmussen et al., 1984; Forder et 
al., 1985). Moreover, inhibtors of PKC, such as polymyxin B, H-7 and HA-1077 
(Asano et al., 1987; 1989) have been shown to produce relaxation of smooth muscle; 
consistent with a role for PKC in tension maintenance (Miller et al., 1986; Khalil &
van Breemen, 1988). Contraction of smooth muscle by phorbol esters involves
2+activation of PKC and is dependent on Ca (Rasmussen et al., 1984; Miller et al.,
1986). It has been hypothesized that PKC is involved in the maintenance rather than 
the initiation of smooth muscle contraction (Rasmussen et al., 1987), because the 
maintenance phase is associated with the phosphorylation of caldesmon and other 
structural and regulatory proteins by PKC, and then are dephosphorylated rapidly 
during relaxation (Park & Rasmussen, 1985; Adam et al., 1989).
Another intracellular second messenger is TK. Tyrosine-specific protein kinase 
activity is known to be associated with oncogene products of the retroviral sic gene 
family (Hunter & Cooper, 1985). This kinase activity is strongly correlated with the 
ability of retroviruses to transform cells, since mutants with reduced kinase activity 
have lower transforming efficiency, and mutants which lack tyrosine kinase activity 
are transformation-defective (Bishop, 1983). Similar kinase activity is also associated 
with the cellular receptors for several growth factros such EGF (Ushiro & Cohen,
1980), PDGF (Ek et al.,1982), insulin (Kasuga et al., 1982) and insulin-like growth 
factor I (Jacobs et al., 1983). Therefore, it is possible that tyrosine phosphorylation 
plays an important role for cell proliferation and cell transformation (Akiyama et al.,
1987).
2+Recent data obtained in cell culture systems pointed to a role for intracellular Ca in
modulating protein tyrosine phosphorylation (Huckle et al., 1990), and a role for
2+
tyrosine kinase activity in the regulation of peptide-stimulated Ca influx (Lee et al., 
1993). Some recent studies have suggested that tyrosine phosphorylation may 
participate in the contractile process and may also exert a modulatory influence on 
calcium channel activity in vascular smooth muscle (Di Salvo et al., 1993; Hollenberg, 
1994; Toma et al., 1995). Several compounds have been reported to inhibit tyrosine 
kinase activity. One such is genistein, an isoflavone compound from fermentation
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broth of pseudomonas sp. Genistein inhibits rather selectively TKs of c-src family, 
including the EGF-URO receptor kinase, without affecting other protein kinases, such 
as kinase C, cyclicAMP-dependent protein kinase, or phosphorylase kinase, at 
concentrations exceeding 100 pg/ml (or 370 jjM ) (Akiyama et al., 1987). The 
synthetic TK inhibitors called tyrphostins (TP), such as RG-50864, represent another 
class of enzyme inhibitors that are pseudo-substrate inhibitors of the enzyme (Gazit et 
al., 1989). Genistein has shown to be a highly specific inhibitor for tyrosine kinases 
but scarcely inhibits the activity of serine and threonine kinases and other ATP 
analogue related enzymes (Akiyama et al., 1987). Adam et al. (1994), found that 
genistein (100 pM) inhibited KCl-dependent contractions of murine aortas and porcine 
carotid arteries by 100% and 91% respectively. In carotid arteries, genistein inhibited 
mitogen-activated protein kinase (MAPK) activity by 40%. The results suggested that 
the effects of genistein are more complex than a simple inhibtion of cellular tyrosine 
kinases, however, the data demonstrate a potential utility for TK inhibitors as 
modulators of vascular tone.
1.4 Influence of the endothelium
1.4.1 Early observations of EDRF and its identification as nitric oxide
In 1980, Furchgott and Zawadzki provided the first experimental evidence 
demonstrating the participation of an endothelium-derived relaxing factor (EDRF) 
in vascular smooth muscle relaxation to acetylcholine. Since then, endothelium- 
dependent relaxation was found to occur in response to a number of 
vasodilators including 5-HT, substance P, adenine neucleotides, bradykinin, 
thrombin and calcium ionophore (A23187) (Furchgott, 1984). These compounds
activate specific receptors at the endothelial cell surface leading to a rapid increase
2+
in the intracellular concentration of free Ca and formation and release of NO. B- 
Adrenergic agonists were originally believed to induce endothelium-independent 
vasodilation. However, recent reports tend to indicate that at least in some 
vascular smooth muscles such as rat aorta (Gray & Marshall, 1992), B- 
adrenoceptor-mediated isoprenaline-induced relaxation is endothelium-dependent 
In many instances, receptor-mediated agonists activate the Na+/H+ exchanger 
leading to an increase in intracellular pH and it would appear that a sustained
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increase in NO formation can be observed following intracellular alkalinization 
(Fleming et al., 1994). Some agents, however, such as the nitrovasodilators, atrial 
natriuretic factor and prostacyclin induce vascular relaxation by endothelium- 
independent mechanisms (Furchgott, 1984). Nitric oxide also functions as a 
powerful toxin released by white blood cells to kill bacteria and tumour cells and a 
messenger molecule in several areas of the brain to transmit nerve signals (Guyton 
& Hall, 1996). Nitric oxide is associated with other structures apart from the 
vascular endothelium. Nitric oxide occurs especially in areas of the brain that are 
responsible for long-term behaviour and for memory. EDRF has a very short half 
life of only seconds in oxygenated physiological salt solutions (Griffith et al., 
1984; Cocks etal., 1985).
The effects of EDRF were found to be inhibited by hemoglobin and methylene blue
(Martin et al., 1985) and to be mediated by stimulation of the soluble guanylate
cyclase with the consequent elevation of intracellular cyclicGMP levels (Rapoport
& Murad, 1983). The nature of EDRF was not known for long time. A
comparison of the biological actions of EDRF and NO on vascular strips and on
platelets showed that the two compounds were indistinguishable (Moncada et al.,
1988). Both EDRF and NO caused relaxation of vascular smooth muscle strips
(Palmer et al., 1987), inhibited platelet aggregation (Radomski et al., 1987a) and
induced disaggregation of aggregated platelets (Radomski et al., 1987b). The
actions of EDRF and NO on vascular strips and on platelets were similarly
2+
potentiated by SOD and cytochrome C and inhibited by Fe and some redox 
compounds (Palmer et al., 1987; Hutchinson et al., 1987).
In mammalian cells, NO is formed from a terminal guanidino-nitrogen of L- 
arginine (Palmer et al., 1988). The reaction is catalysed by the enzyme, nitric oxide 
synthase (NOS) yielding L-citrulline as a coproduct of this reaction. Four 
cofactors (heme, FMN, FAD and H4 biopterin) and two cosubstrates (02 and 
NADPH) participate in enzymatic NO formation (Fig. 4). Several isoforms of the 
NOS have been isolated and purified (Table 4) (Schmidt et al., 1991). These 
include constitutive (cNOS) and inducible (iNOS) forms of the enzyme. Inducible 
form is expressed in response to pathological stimuli while the constitutive 
enzyme is present under physiological conditions. The constitutive form is
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Cell type Brain, N A N C  nerves, etc. M acrophage, leukocyte, 
V SM C , etc.
Endothelium only
MW 160 kDa 130 kDa 135 kDa
Calcium Dependent Independent Dependent
Inducibility Constitutive Inducible Constitutive
Solubility Soluble Soluble Particulate
Human chromosome 12 17 7
2+
cytosolic, Ca /calmodulin dependent and releases NO for short periods in response 
to receptor or physical stimulation. NO released by this enzyme acts as a 
transduction mechanism underlying several physiological responses (Moncada et 
al., 1991). The other form of the enzyme, is induced after activation of 
macrophages or endothelial cells and synthesizes NO for long periods (4-6hr) 
(Moncada et al., 1991; Corbett et al., 1993; Marczin et al., 1993). Like the cNOS, 
inducible NO synthase is also a predominantly cytosolic enzyme with essentially 
the same cofactor requirements as the constitutive enzyme (Cho et al., 1992).
1.4.2 Inhibition of NO synthesis
A number of compounds have been shown to inhibit the activity of NO synthase. 
These include L-NMMA (Palmer & Moncada, 1989; Moore et al., 1989; Mayer et 
al., 1989; Ress et al., 1989); L-NOARG ; L-NIO (Rees et al., 1990a,b) and 7-NI 
(Babbedge et al., 1993; Moore et al., 1993). The different potencies shown by these 
compounds in vascular tissue in vitro and vivo may be due to differences in uptake, 
distribution or metabolism of compounds. There is also a regional variation in the 
sensitivity of constitutive NOS to the inhibitors. Specifically, while 7-NI was 
potent against brain NOS, it was inactive against NOS in peripheral tissues 
(Babbedge et al., 1993; Moore et al., 1993). Perhaps this would suggest that the 
constitutive NOS is not homogenous. This selectivity could be advantageous when 
brain and not peripheral NOS is to be inhibited.
Aminoguanidine, a bifunctional molecule containing the guanido group of L- 
arginine linked to hydrazine, is equipotent to L-NMA as an inhibitor of cytokine- 
induced NO formation (Corbett et al., 1992), but is about 100-fold less potent as an 
inhibitor of the constitutive form (Misko et al.,1993).
The glucocorticoids, (dexamethasone, hydrocortisone and cortisol) inhibit the 
inducible but not constitutive form of NOS in vitro in vascular endothelial cells 
(Radomski et al., 1990). The finding that the glucocorticoids inhibit the induction 
of NOS is of special significance since it may explain , at least in part, the 
therapeutic and toxic action of these compounds (Moncada et al.,1991).
1.4.3 Endothelium-dependent NO-independent relaxation
As well as relaxing vascular smooth muscle in an endothelium-dependent fashion 
(by releasing EDRF), acetylcholine and other muscarinic agonists also stimulate
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endothelium-dependent smooth muscle hyperpolarization (Bolton et al., 1984; 
Chen et al., 1988; Vanhoutte, 1988; Garland & McPherson, 1992). Smooth muscle 
hyperpolarization to acetylcholine, like the relaxation, is mediated, at least in part, 
by the release of a diffusible factor (Feletou & Vanhoutte, 1988; Chen et al., 1991). 
In contrast to the relaxation induced by acetylcholine, hypeipolarization was not 
blocked by either oxyhaemoglobin or methylene blue, leading to the suggestion that 
a separate hyperpolarizing factor (EDHF) was released simultaneously with EDRF 
(Chen et al., 1988; Taylor & Weston, 1988). Furthermore, it was suggested that 
EDHF might have a predominant role in small arterioles (Nilsson et al., 1994).
1.4.4 Endothelium-dependent vasoconstriction
Besides EDRF, the endothelium can release substances that induce or augment 
contraction of the underlying smooth muscle. This suggestion was made first on 
the basis of experiments in canine femoral arteries where the removal of the 
endothelium reduced the contractions of potassium ions (De Mey & Vanhoutte,
1981). It was later found that in isolated arteries and veins, rapid endothelium- 
dependent increase in tension can be obtained which are explained best by the 
production of mediators that activate the underlying vascular smooth muscle. 
These substances have been called endothelium-derived contracting factors) 
(EDCF) (Fig. 5) (Vanhoutte, 1987; Vanhoutte et al., 1991; Thulesius et al., 1988). 
It has been found that in certain blood vessels (peripheral veins and large cerebral 
arteries), the endothelium releases vasoconstrictor substances among which are 
superoxide anion and thromboxane A2. The release of these endothelium-derived 
vasoconstrictors may contribute to the autoregulatory processes. Other stimuli 
which induce the release of vasoactive substances from the endothelium include 
arachidonic acid, thrombin and anoxia (De Mey & Vanhoutte, 1982; Rubanyi & 
Vanhoutte, 1985). Moreover, acetylcholine and serotonin induced the release of 
EDCF in vessels from spontaneously hypertensive rats (Luscher & Vanhoutte, 
1986). Rapid stretch was found to evoke a transient contraction in canine basilar 
arteries with, but not in those without endothelium. These observations suggest that 
endothelial cells can act as sensors of changes in distension (Vanhoutte, 1987).
28





Fig. 5 A number o f physicochemical stimuli, neurohumoral mediators [Ach, 
adenine diphosphate (ADP), 5-HT] and arachidonic acid (AA) can evoke 
endothelium-dependent contractions in certain blood vessels, presumably by the 
release of EDCF(s). (Vanhoutte et al., 1991)
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1.5 Objectives of the study
It has been suggested that ovum maturation is a direct function of blood flow to the 
ovary (Virutamasen et al., 1971). It is expected that changes in blood flow would alter 
the delivery of hormones (FSH and LH) to the ovary. This in turn would influence 
the availability of hormones to receptors in the granulosa (which has no direct nerve 
supply) and, as a consequence, influence the onset of changes leading to follicular 
maturation. Since the major part of the adrenergic nerves in the ovary are perivascular, 
it seems logical to assume that a noradrenergic process would regulate tone of the 
ovarian vascular bed. Modulation of the adrenergic mechanism in the ovarian vascular 
bed would therefore be expected to interfere with tone of the vessels and hence blood 
flow to the ovary.
It has been reported that blood flow to the ovaiy is decreased by NA (Wurtman, 1964). 
This is consistent with an in vitro demonstration of NA-induced vasoconstriction in the 
perfused rabbit (Graham and Sani, 1971), ewe (Kuhl et al., 1974), and human (Varga 
et al., 1979) ovarian arteries. These studies did not elucidate the subtype(s) of a- 
adrenoceptors involved in NA-induced responses. Oriowo & Bevan (1986) have 
shown that a  j -adrenoceptors mediated NA-induced contraction of ring segments of the 
ovarian artery. However, reactivity of the main (muscular artery) may not always 
represent the pattern of reactivity in the whole vascular bed. For example, Graham & 
Sani (1971) showed that the perfused rabbit ovarian vascular bed was less sensitive to 
NA (compared with the ovarian artery). In the vascular bed, the arterioles are usually
assumed to be the main site of agonist action. It has been shown that the arterioles
2+
differ from the muscular arteries in their Ca handling mechanisms and in the 
distribution of receptors (Cauvin et al., 1984; Cauvin & Malik, 1984).
The objectives of this study are therefore to:
1. identify the adrenergic receptor sub-type(s) in the ovarian vascular bed,
2 . study the influence of the vascular endothelium on responses to agonists in control 
and hormonally-treated rabbits,
3. study the signal transduction mechanism(s) mediating adrenergic responses,
4. study the effect of hormonal changes (including pregnancy) on a-adrenergic 




2.1 Materials used in the study
2.1.1 Drugs
(-)Noradrenaline hydrochloride, phenylephrine hydrochloride, yohimbine 
hydrochloride, verapamil hydrochloride, polymyxin B sulfate, oestradiol-17B, 
histamine hydrochloride, (±)propranolol hydrochloride, DOCA (deoxycorticosterone 
acetate), sodium nitroprusside (SNP), 6-hydroxy dopamine (6-OHDA), CHAPS (3- 
[(3-cholamidopropyl) dimethyl-ammonia] 1-propanesulfonate) and EGTA 
(ethyleneglycol-bis-(B-amino ethyl ether) N,N,N’,N’-tetra acetic acid) were obtained 
from Sigma chemicals, (St Louis, MO, USA).
LY-83,583 (6-phenylamino)-5,8-quinolinedione, phentolamine mesylate, genistein, 
nifedipine, oxymetazoline hydrochloride, ryanodine, HA-1077 (l-(5-
isoquinolinylsulfonyl)-homopiperazine dihydrochloride), WB-4101 (2-(2,6-
dimethoxyphenoxyethyl)aminomethyl-l,4-denzodioxane hydrochloride), SZL-49 
(prazobind), CEC (chloroethylclonidine dihydrochloride), prazosin hydrochloride, 
UK14,304 (5-bromo-N-(4,5-dihydro-1 H-imidazo;-2-yl)-6-quinoxalinamine), clonidine 
hydrochloride, (±)isoprenaline bitartrate, carbachol, aminoguanidine hemisulfate, N°- 
nitro-L-arginine (L-NOARG), , N°-nitro-D-arginine (D-NOARG),, methylene blue 
and S-(+)-niguldipine hydrochloride were obtained from Research Biochemicals 
International (RBI), Natick, MA, USA. L-ascorbic acid was obtained from BDH 
Chemicals Ltd. Tizanidine and SDZ NVI085 were gifts from Sandoz pharma, Basle, 
Switzerland ; and methoxamine hydrochloride was from Borough Wellcome 
Company. Cocaine hydrochloride was a gift from Professor C. Pilcher, Pharmacology 
dept., Faculty of medicine, Kuwait University. U46619 was obtained from Cayman, 
B-HT 920 (5,6,7,8-tetrahydro-6-(2-propenyl)-4H-thiazolo[4,5-d]azepin-2-amine 
dihydrochloride) from Beecham and HCG (human chorionic gonadotrophin) from 
local pharmacy.
Stock solutions of SZL-49, prazosin, deoxycorticosterone acetate, nifedipine, U46619 
and indomethacin were made in absolute ethanol and diluted fresh with Krebs’ 
Henseleit solution (KH-solution) each day of the experiment, while all other drugs 
were dissolved in 0.1 N hydrochloric acid or distilled water.
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2.1.2 Physiological solutions
In all experiments, KH-solution was used. The composition was as follows (mM):
NaCl (118.3), KC1 (4.7), CaCl2 (2.5), MgS04 (1.2), NaHC03 (25), KH2P04 (1.2) and 
glucose (11.2). The pH was 7.4. The solution was gassed with a mixture of 5% C02 
and 95% 0 2.
Different concentrations of KC1 solution (20, 40, 60, 80 and 100 mmoles) were  ^ , 
prepared by substituting KC1 in the normal KH-solution.
Composition of 80mM KC1 depolarized solution:
NaCl (118.3), KC1 (80), MgS04 (1.2), NaHC03 (25), KH2P04 (1.2) and glucose 
(11.2).
2.1.3 Choice of animal species
The investigations were carried out using the rabbit ovarian vascular bed. The choice 
of this vascular bed as the model was dictated by the following:
1. The rabbit is a non-cycling animal and therefore the influence of circulating 
hormones and hence variations in responses arising from varying levels of circulating 
hormones on agonist responses would be minimal.
2. Following coitus or HCG injection, ovulation takes place in the rabbit in about 12 
hrs and therefore reactivity of the ovarian vascular bed during the periovulatory period 
can easily be studied.
3. The perfused rabbit ovary has been used extensively to study the ovulatory process 
in vitro (Wallach et al., 1978; Hamada et al., 1979; Kobayashi et al., 1981; 1983a; 
1983b).
4. Finally, it is a convenient laboratory animal to handle.
2.1.4 Isolation of the ovarian vascular bed
Sexually mature female New Zealand White (NZW) rabbits, weighing 3.0-4.0 kg, 
were used in these experiments. The rabbits were anaesthetized with i.v. 
pentobarbitone sodium (50 mg/Kg) given i.v. via the marginal ear vein. Thereafter, the 
animal was exsanguinated by cutting the carotid artery. The abdominal cavity was 
opened up and the ovarian artery was identified (Fig. 6). The fatty tissue surrounding 
the ovarian bed was removed by pressing gently on both sides with the fingers. Then 
the vessel was cleared of as much fat as possible without damaging the artery. 
Branches of the ovarian artery were tied using surgical silk ligature (branches were
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Fig.6 A photograph showing the rabbit ovarian vascular bed in situ; ovary (o), ovarian 
artery (oa) and branching of ovarian artery (b).
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previously identified by injecting methylene blue dye into the ovarian arteiy through 
the abdominal aorta). The ovary was then separated from the adjacent tissue and made 
ready for isolation.
The ovarian artery was handled carefully, its origin was identified at its junction with 
the abdominal aorta, and the aorta was tied on both sides of the vessel. Finally the 
abdominal aorta was cut at both sides and the ovarian bed was isolated and transferred 
into a Petri dish containing KH-solution (Fig. 7). The ovarian bed was weighed before 
and after each experiment.
The ovarian bed was placed on a warm chamber filled with water circulating at 37°C 
and the ovarian arteiy was cannulated, using a polyethylene cannula (Fig. 8). The 
preparation was then perfused with KH solution (at 37°C), aerated with 95% oxygen 
and 5% carbon dioxide, delivered at a flow rate of 6 ml/min using a multichannel 
masterflex pump (7519-00). The perfusion pressure was recorded via a pressure 
transducer (SensoNor 840) connected to a Lectromed (2 channel recorder) (Fig. 9). 
The preparation was always left for at least 30 minutes to stabilize. A bolus injection 
of NA was usually given at the begining of the experiment as a test dose. Thereafter, 
successive doses of the agonists were given at regular intervals to generate a dose- 
response curve. This was repeated at least twice to ascertain reproducibility.
2.2 Experimental procedure
The reactivity of isolated vascular smooth muscle to NA is influenced by a number of 
factors including, uptake mechanisms (neuronal and extraneuronal); simultaneous 
activation of B-adrenoceptors which by a process of physiological antagonism reduce 
the vasoconstrictor response; release of prostanoids which could result in either an 
enhancement or reduction of NA response depending on the relative proportions of 
vasoconstrictor and dilator prostanoids. Finally, reactivity is also modulated by 
endothelium-derived relaxing factors).
The primary objective of these preliminary studies was to examine the effect of 
blocking uptake processes, B-adrenoceptors and generation of prostanoids on the 
vasoconstrictor responses to NA in an attempt to define the optimum conditions to be 




Fig.7 A photograph of an isolated rabbit ovarian vascular bed; ovary (o), ovarian artery 
(oa) and abdominal aorta (aa).
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Fig.9 A schematic representation of the in vitro perfusion system used in this study.
2.2.1 Preliminary experiments
2.2.1.1 Influence of time on the responses to NA
One disadvantage of the perfused whole vascular bed is that with time, the tissue 
becomes oedematous and this could affect either the basal perfusion pressure or 
agonist response or both. Experiments were therefore designed to assess the 
responsiveness of the ovarian vascular bed to NA over a period of time. In this series 
of experiments, after the period of equilibriation up to 4 consecutive NA-dose response 
curves, at 45 min intervals, were obtained. In addition, the ovarian vascular bed was 
weighed before perfusion and at the end of the experiments. The difference in weight 
was taken as an index of oedema formation.
2.2.1.2 Effects of uptake and O-adrenoceptor blockade on responsiveness to NA 
After obtaining control NA dose-response curves, propranolol (lO^M) was added to 
the perfusion fluid and allowed to equilibriate with the tissue for 30 min before re­
establishing the NA dose-response curve. The same procedure was adopted in testing 
the influence of uptake blockers; cocaine (uptakej) and DOCA (uptake^ on NA- 
evoked vasoconstrictions. Only one inhibitor was tested on each preparation. 
However, in one series of experiments, the effect of a combined blockade of uptake 
and B-adrenoceptors on noradrenaline-evoked vasoconstriction was tested by adding 
all the inhibitors, i.e. propranolol (lO^M), cocaine (3xlO'6M) and DOCA (10'5M) to 
the perfusion fluid and allowing a 30 min. contact time before repeating the NA dose- 
response curve.
2.2.13 Effects of indomethacin on NA-induced vasoconstriction
The influence of endogenously generated prostanoids in modulating the 
vasoconstrictor response to NA was tested. After obtaining a control NA-dose 
response curve, indomethacin (5x1 C^M) was added to the perfusion fluid and allowed 
to perfuse for 30 min before repeating NA-doses.
2.2.1.4 Effects of other agonists on NA-induced vasoconstriction 
The effect of agonists other than adrenergic agonists on the ovarian vasculature was 
also studied. Dose-response curves were established for histamine, angiotensin II and 
bradykinin using a procedure to that used for NA.
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2.2.1.5 Electrical stimulation of the perfused ovarian vascular bed
For electrical stimulation, the ovarian artery was passed through a platinum ring 
electrode. The electrode was placed close to the bifurcation of the artery into smaller 
branches. This is because there is evidence that adrenergic innervation increases as the 
vessel diameter decreases (Bumstock, 1975).
Preliminary experiments were also performed to determine the optimum conditions 
(voltage and pulse duration) for electrical stimulation. Briefly, electrically-induced 
vasoconstrictor responses (at a fixed frequency) were obtained at various voltages 
ranging from 30-70V in order to determine the maximum voltage for stimulation. This 
voltage was then used to determine the optimum pulse duration at which there will be 
no direct muscle stimulation. In these experiments, the preparation was stimulated at 
70V, 40Hz (for 30 sec.) using pulse durations ranging from 0.5-3.0 msec.
2.2.2 Influence of the vascular endothelium
2.2.2.1 Effects of endothelial cell removal on agonist-induced responses
In this series of experiments, the ovarian vascular bed was perfused with KH-solution 
containing CHAPS 4.7 mg/ml for 30 seconds (Tesfamariam & Halpem, 1987; Moore 
etal., 1990), after which the tissue was perfused with normal KH-solution for 30 min 
before the NA dose-response curve was repeated. Loss of endothelial function was 
assumed when carbachol (1000 nmoles) failed to dilate the NA-preconstricted 
vascular bed.
2.2.2.2 Effects of NOS inhibitors on NA-induced vasoconstriction
2.2.2.2.1 Effects of L-NOARG and D-NOARG on NA-induced vasoconstriction
L-NOARG, an inhibitor of cNOS, was used to study the effect of the endothelium- 
derived NO on reactivity of the ovarian vascular bed to NA. Control dose response 
curves for NA were established as in the previous sets of experiments. Then, the tissue 
was perfused with KH-solution containing L-NOARG (10*6M-10“4M) for 30 min. 
Thereafter, and still in the presence of L-NOARG, a dose response curve for NA was 
re-established. In another series of experiments, D-NOARG at concentrations of 10’5M 
and lO^M, was used.
Experiments were also performed to determine whether or not the effect of L-NOARG 
could be reversed by L-Arginine. Dose-response curves were obtained for NA in the
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absence and in the presence of L-NOARG (10'5M). Thereafter, L-arginine (5x1 O^M) 
was added to the KH-solution (containing L-NOARG, 10‘5M) and allowed to perfuse 
the ovarian bed for 30min before repeating NA dose-response curve.
2.2.2.2.2 Effects of aminoguanidine on NA-induced vasoconstriction 
Control NA dose-response curve was established as usual. The ovarian vascular bed 
was then perfused for 30 min with aminoguanidine (10‘5M-10^M) before the NA 
dose-response curve was re-established. A similar set of experiments, was performed 
after removing the endothelium with CHAPS 4.7mg/ml, using aminoguanidine at a 
concentration of lO^M.
2.2.2.3 Effects of NOS inhibitors on agonist-induced vasodilator responses
In order to obtain dilator responses, the perfusion pressure was raised with NA 
(10'5M) infusion. When a steady perfusion pressure was obtained, bolus injections of 
the agonists carbachol, isoprenaline and SNP were given and vasodilator responses 
were recorded. After obtaining control responses, L-NOARG (10'5M) was added to 
the KH solution and was allowed to equilibriate with the tissue for 30 min before 
repeating agonist responses.
2.2.2.4 Effects of cyclicGMP inhibition on agonist-induced vasodilator responses
In order to determine whether or not vasodilator responses involved accumulation of 
cyclicGMP, the effect of cyclicGMP inhibitor, LY-83,583 was tested on carbachol-, 
isoprenaline- and SNP-induced vasodilator responses. Dose-response curves for 
carbachol were established after raising the basal perfusion pressure with NA (10‘5M). 
Thereafter, LY-83,583 (10‘5M) was added to the KH-solution and was allowed to 
perfuse the preparation for 10 min before repeating the carbachol dose-response curve. 
The cyclicGMP inhibitor was tested against only single doses of isoprenaline and SNP 
(100 nmoles). Another set of experiments was performed to verify the role of 
cyclicGMP in mediating the vasodilator responses of carbachol and SNP; using the 
cyclicGMP inhibitor, methylene blue. A similar protocol was followed as with LY 
83583 after raising the basal perfusion pressure with NA (10'5 M). The preparation 
was perfused with methylene blue (3x10‘5 M) for 15 min before repeating agonsit- 
induced vasodilator responses.
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2.2.3. Identification and characterization of adrenoceptors in the ovarian 
vascular hed
2.23.1 Identification of adrenergic receptors
A number of adrenergic agonists were used to identify the adrenergic receptors present 
in the ovarian vascular bed. The procedure consisted of establishing a control NA 
dose-response curve. This was to serve as the reference control curve against which 
other agonists would be compared. Thereafter, dose-response curves were established 
for the other agonists including methoxamine, oxymetazoline, phenylephrine, SDZ 
NVI 085, tizanidine, clonidine, B-HT 920 and UK 14, 304. It was not possible to test 
all the compounds on the same preparation, but in any experiment three or four 
compounds were tested in addition to NA which was the reference agonist. In all 
experiments, two consecutive dose-response curves were separated by 45-60 min 
intervals.
Isoprenaline, a non-selective B-adrenergic agonist, was used to test for the presence of 
B-adrenoceptors in the ovarian vascular bed. The procedure consisted of establishing a 
dose-response curve for isoprenaline in the "low tone preparation". Thereafter, 
perfusion pressure of the ovarian bed was raised by perfusing the preparation with KH- 
solution containing 10‘5M methoxamine or NA. After achieving a stable increase in 
perfusion pressure, increasing concentrations of isoprenaline were injected to establish 
a dose-response curve. To further confirm the presence of B-adrenoceptors, the 
preparation was perfused with KH-solution (with 10’5M methoxamine or NA) 
containing propranolol (lCT^-lO^M) for 30 min before re-establishing the 
isoprenaline dose-response curve.
2.23.1.1 Effects of prazosin and yohimbine on agonist-induced contractions
The effects of a  -adrenoceptor subtype-selective antagonists on agonist-induced 
vasoconstriction were examined in order to characterize a-adrenergic receptor 
subtype(s) in the ovarian vascular bed. Antagonist potencies were expressed as pA2 
values determined according to the method described by Arunlakshana and Schild 
(1959), (pA2 is the negative logarithm to base 10 of the concentration of an antagonist 
that makes it necessary to double the concentration of agonist needed to elicit a given 
submaximal response).
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Briefly, after obtaining control responses to NA, the KH solution was changed to one 
containing various concentrations of prazosin (10~8M-10"5M). The antagonist was 
allowed to equilibriate with the tissue for 30 mins before re-establishing the NA dose- 
response curve. From the curves, ED50 values were obtained and these were used to 
calculate dose-ratios (DR). The concentration ratio is the ratio of the concentrations of 
NA giving an equal response (50%) in the presence or in the absence of the antagonist. 
A plot of log (DR-1) against antagonist concentration (M) was then made. The X- 
intercept of the regression line as well as the slope were obtained. The X-intercept is 
the pA2 value corresponding to the antagonist concentration (M), which requires a 
doubling of the agonist concentration to produce the same response as in the absence 
of the antagonist. Antagonism was assumed to be competitive when the Schild 
regression line had a slope not significantly different from 1.0 .
Other agonists were also tested in the presence of various concentrations of prazosin. 
One concentration of prazosin (3xl0‘7M) was used against methoxamine and SDZ 
NVI 085 because a large suppression in the maximal agonist response was noticed 
after incubation with antagonist concentrations greater than or equal to 3xl0‘ M. In 
another series of experiments, yohimbine (10‘7M-10‘5M) was tested against NA and 
phenylephrine.
The effects of prazosin and yohimbine on vasoconstrictor responses evoked by 
electrical stimulation were also studied. In this series of experiments, responses were 
obtained in the absence, and in the presence of varying concentrations of the 
antagonist. Each antagonist concentration was allowed to perfuse the preparation for 
30 min before stimulation.
2.23.2 Characterization of cq-adrenoceptor subtypes
The a!-adrenoceptor subtype(s) mediating agonist-induced vasoconstriction in the 
perfused ovarian vascular bed were investigated. This involved examining the effect of 
subtype-selective antagonists (competitive and alkylating) on agonist-induced 
vasoconstriction in the vascular bed.
2.23.2.1 Competitive antagonists
Following the period of equilibriation, two to three consecutive NA dose-response 
curves were obtained. The last curve was routinely used as the reference control curve
o <
after which, ascending concentrations of WB-4101 (10 M-10” M) were added to the
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KH-solution perfusing the ovarian vascular bed. The antagonist was allowed to 
equilibriate with the tissue for 30 min before re-establishing the dose-response curve 
for NA. Antagonist potency was expressed as the pA2 value obtained as described for 
prazosin. A similar experimental procedure was used to study the effect of other 
adrenoceptor agonists including phenylephrine, methoxamine, oxymetazoline and 
SDZ-NVI 085. Different concentrations of WB- 4101 were added to the KH-solution 
perfusing the ovarian vascular bed. The antagonist was allowed to perfuse the tissue 
for 30 min before re-establishing the agonists dose-response curves. Four 
concentrations of the antagonist were used against phenylephrine and oxymetazoline. 
Antagonist potency was expressed as pA2 value obtained as described for prazosin. 
However only one concentration of WB-4101 (3xlO'7M) was used against 
methoxamine and SDZ-NVI 085 because concentrations more than 3x10" M 
significantly suppressed the maximum response to these agonists. In this case, 
antagonist potency was expressed as (pKB) values determined according to the 
equation of Furchgott (1972):
Kb= [antagonist] M 
DR-1
The effect of WB-4101 on vasoconstrictor responses evoked by electrical stimulation 
was also investigated. The response to stimulation was obtained in the absence and 
also after incubation with varying concentrations of the antagonist Each antagonist 
concentration was allowed to perfuse the preparation for 30 min before stimulation 
was applied.
2.23.2.2 Irreversible antagonists
Control dose-response curves for NA, phenylephrine, oxymetazoline, methoxamine 
and SDZ NVI 085 were established as usual. The ovarian vascular bed was then 
perfused with KH-solution containing a concentration of 5x1 O^M of the irreversible 
alkylating antagonist SZL-49 for 30 min after which the vascular bed was perfused 
with drug free KH-solution for at least another 30 min before repeating agonists dose- 
response curve. A similar procedure was also used to test the effect of CEC (3xlO‘5M- 
10"4M) on NA and oxymetazoline induced contractions of the ovarian vascular bed.
The effects of CEC and SZL-49 on vasoconstrictor responses evoked by electrical 
stimulation were studied. In this series of experiments, responses were obtained before
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and after perfusing the preparation with SZL-49 (5x1 O^M) or CEC (l(rtvl) as 
described above.
2.2.4 Signal transduction mechanisms
The objective of this set of experiments was to study the signal transduction 
mechanisms involved in the vasoconstrictor response of the ovarian vascular bed to 
several agonists.
2.2.4.1 Calcium-free solution
A control dose-response curve for NA was established as usual. The preparation was 
then incubated in Ca2+-free KH-solution ( with or without EGTA 2mM) for 30 min 
before re-establishing the NA dose-response curve.
In another set of experiments, the time-course of the loss of vasoconstrictor effect to
y*
NA in Ca -free solution (with or without EGTA) was determined. A vasoconstrictor 
response to a submaximal dose of NA was obtained (300 nmoles) and this was
y*
repeated until constant. The normal KH-solution was then replaced with Ca free-
KH-solution (with or without EGTA) followed by bolus injections of NA at 10-15
2+
min intervals (the first administration was given 5 min after perfusion with Ca -free 
solution).
2.2.4.2 Calcium channel blocking agents
A control NA dose-response curve was established as usual. The ovarian vascular bed 
was then perfused with KH-solution containing verapamil (10‘7M-10"5M) or
o c
nifedipine (10 M-10' M) for 30 min before repeating the NA dose-response curve. 
Since it has been shown in different preparations, that partial agonists are more
yt
susceptible to blockade by Ca channel antagonists (Ruffolo & Nichols, 1988), the 
effect of the calcium channel blockers, verapamil and nifedipine were tested against 
vasoconstrictor responses induced by SDZ NVI 085, which is a partial agonist, in the 
ovarian vascular bed.
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In another set of experiments, responses to calcium channel antagonists were tested 
against KCl-induced vasoconstriction. The ovarian vascular bed was injected twice 
with 200 pmoles of KC1 solution at 5 min intervals to establish steady control 
responses. Thereafter, the preparation was perfused with KH-solution containing 
different concentrations of verapamil and nifedipine for 30 min before repeating the 
injection of KC1 solution.
2.2.43 Effects of inhibitors of intracellular calcium release
In order to determine whether a release of intracellular Ca2+ was involved in NA- 
induced vasoconstriction, the effect of ryanodine on NA-induced vasoconstriction was 
examined. The protocol was as follows. After establishing a NA dose-response curve, 
the ovarian vascular bed was then perfused with KH-solution containing ryanodine 
(10'5M) for 30 min before repeating the NA dose-response curve.
2.2.4.4 Effects of protein kinase C inhibitors
After establishing control NA dose-response curves, the ovarian vascular bed was then 
perfused with KH-solution containing HA-1077 (3xlO‘7M-3xlO"6M) for 30 min before 
repeating the NA dose-response curve. The same procedure was used to study the 
effects of polymyxin B (lO^M-lO^M). Another set of experiments involved 
depolarization of the ovarian vascular bed with 80 mM KC1 depolarized KH-solution. 
A single dose of CaCl2 solution (100 pM) was given at 15 min interval antil a steady 
and reproducible response was established. Thereafter, the preparation was perfused 
with the PKC inhibitors, HA-1077 (3x10*7 M -3 xlO”6 M) and polymyxin B (1 0 "^  - 
lO^M). Perfusion with the PKC inhibitors was allowed for 30 min at each 
concentration, before repeating the injection with CaCl2.
2.2.4.5 Effects of tyrosine kinase inhibitor
In this series of experiments, control dose-response curves were established for NA in 
the perfused ovarian vascular bed. Thereafter, the preparations were perfused with 
KH-solution containing genistein (lO^M-lO^M) for 30 min before repeating the NA 
dose-response curves.
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2.2.5 Effect of hormonal changes on vascular reactivity
2.2.5.1 Effect of ovulation induction with HCG
A group of 6 NZW rabbits weighing 3.0-4.0 Kg were used for this study. Each rabbit 
was injected with 100 I. U. of HCG intravenously (Greenwald, 1963; Shmidt et al., 
1985), 12 hours prior to sacrificing it for experiment.
2.2.5.2 Effect of 17-B-oestradiol
A group of 5 NZW rabbits (3.0-4.0 Kg) were injected intramuscularly with 5mg/rabbit 
of oestradiol 1713-propionate and used one week later.
In another sereis of experiments, a dose-response curve for NA was established as 
usual. Thereafter, 17-B-oestradiol was added to the KH-solution perfusing the ovarian 
vascular bed at concentrations of 3xlO’9M- 3xl0'5M. The ovarian vascular bed was 
incubated for 30 min with these different concentrations before repeating the NA dose- 
response curve.
2.2.5.3 Effect of pregnancy
A group of 20 NZW rabbits (3.0-4.0 Kg) were mated and separated individually. After 
three weeks of gestation, the animals were sacrificed and the ovarian vascular bed was 
isolated in the usual manner.
2.2.5.4 Experimental procedure
The following procedure was used to study the rabbit ovarian vascular bed in these 
different groups of the rabbits. Vasoconstrictor responses to NA were recorded as 
usual. Following the NA control curve, dose-response curves were also established for 
oxymetazoline and histamine. The influence of the endothelium in the different 
groups of the treated and pregnant rabbits was studied, where the effect of L-NOARG 
(10’5M) on NA-induced vasoconstriction was studied. After establishing a control 
NA-dose-response curve, the preparation was treated with L-NOARG (10‘5M) for 30 
min before repeating the NA dose-response curve. In another set of experiments, the 
basal perfusion pressure was raised by NA (10’5M) to study the relaxant responses to 
carbachol and SNP before and after incubation with L-NOARG (10‘5M). Regarding 
the pregnant rabbits, they were compared with the controls for the idetification of a- 
adrenoceptors. The ovarian vascular bed was incubated either with yohimbine (10’5M) 
or prazosin (10'7M) for 30 min before repeating the NA dose-response curve. 
Vasoconstrictor responses to NA were also tested after treating the preparations with
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CEC (3x10‘5M) or SZL-49 (5x1 O^M). The influence of the endothelium on the partial 
agonist, oxymetazoline, was also studied in the pregnant rabbits, using L-NOARG 
(10'5 M).
2.3 Statistical analysis
Data are presented as mean + s.e. of 'n' number of experiments. Where necessary, 
mean values were compared using Student's t-tests or paired as appropriate. The 
difference was considered to be significant when p value was less than 0.05. The 
degree of significance is indicated as follows: 





3.1.1 Influence of time on the responses to NA
NA (0.1 - 1000 nmoles ) produced ol c lo s e -  dependent vasoconstriction in the 
perfused rabbit ovarian vascular bed. The vasoconstricting effect of NA was 
maintained over a 5hr period as concentration response curves established at 45min 
intervals were reproducible (Fig. 10). Responsiveness of the preparation usually 
persisted for as long as 7-8 hr of perfusion. Reproducibility and stability of response 
of the preparation was found adequate for studying the the reactivity of ovarian 
vascular smooth muscle. The mean basal perfusion pressure was 41.7±3.3 mmHg 
(n=20). There was a significant increase in weight of the ovarian bed taken at the end 
of the experiment (1 .lgm ± 0.2 in the beginning, compared to 1.7 gm ± 0.2 at the end 
of the experiment) indicating that there was some oedema formation. This was 
however, not accompanied by a change in the basal perfusion pressure or the response 
of the vascular bed to agonists
3.1.2 Effects of uptake inhibitors and fl-adrenoceptor blockade on responsiveness 
toNA
Neither DOCA (10’5M) nor cocaine (3x1 O^M) or propranolol (lO-6^  altered the basal 
perfusion pressure of the ovarian vascular bed. A combination of them (the three 
inhibitors) did not significantly enhance NA response in the perfused ovarian vascular 
bed (p> 0.05) (Fig. 11).
3.13 Effects of indomethacin
A possible role for prostanoids in modulating vasoconstrictor response to NA was also 
examined. After obtaining a control NA dose-response curve, indomethacin (5x10-6^  
was included in the KH-solution and allowed to perfuse the preparation for 30 min 
before repeating NA dose-response curve. The results showed that indomethacin 
(5x10"6) did not enhance NA-induced pressor responses (Fig. 12)
3.1.4 Effects of other agonists
Several agonists were tested for their vasoconstrictor responses on the perfused rabbit 
ovarian vascular bed, apart of NA. Different concentrations of KC1 (20, 40, 60, 80 & 
100 mmoles) were perfused through the ovarian vascular bed until a maximum 
constrictor level was established, before returning back to the normal KH-solution. A 
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Fig. 10 Consecutive dose-response curves to NA obtained at 45 min intervals in the 
perfused rabbit ovarian vascular bed (mean±se, n=5-7).
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Fig. 11 NA-induced vasoconstriction in the perfused rabbit ovarian vascular bed (O) 




















Fig. 12 Effect of indomethacin, 5x1 ( • )  on NA-induced vasoconstriction (O) in the
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Fig* 13 KCl-induced vasoconstrictor response in the perfused rabbit ovarian vascular 
bed (mean±se, n=4).
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mmoles corresponded to 81.1% of maximal response and was chosen to be used in the 
subsequent experiments involving tests for the integrity of endothelium.
Vascular responses to bradykinin, angiotensin II and histamine were also investigated 
(Fig. 14). Bradykinin had no effect on the ovarian vascular bed unless the basal tone 
was raised with NA (10’5M).
3.1.5 Effects of electrical stimulation
There was a voltage-dependent (at a fixed frequency and pulse duration) 
vasoconstrictor response to electrical stimulation. As shown in Figure 15a, the 
maximal vasoconstriction was produced at 60-70 volts. Therefore, supramaximal 
voltage (70V) was chosen and used in the subsequent experiments. A frequency- 
response relationship at 70 volts and 0.5 msec, revealed that a frequency of 40 HZ 
produced a submaximal response (Fig. 15b). In the second series of experiments, 
different pulse durations (0.5-3.0 msec) were tested. The results showed that 
electrical stimulation produced a reliable reproducible response at 0.5 msec pulse 
duration. The response increased with increasing pulse duration up to 3 msec which 
was the highest pulse duration tested. In order to confirm that the response to 
electrical stimulation was neurogenic, tetrodotoxin (3xlO"7M) was included in the 
perfusion fluid and allowed to perfuse the tissue for 30 min before repeating electrical 
stimulation. It was observed that only responses at 0.5 msec pulse duration were 
abolished by TTX (Fig. 16) while at other pulse durations, the responses were resistant 
to TTX, indicating direct muscle stimulation. Accordingly, the parameters chosen to 
produce optimum response to electrical stimulation were a voltage of 70V and a pulse 
duration of 0.5 msec. A typical trace of the vasoconstrictor response of the ovarian 
vascular bed to electrical stimulation (at 70 V, 0.5 msec and 40 HZ) is shown in 
Figure 17. The maximum increase in vasoconstrictor response to electrical stimulation 
at optimum conditions was 28.4 % of the maximum response to NA.
In order to determine whether or not the response to electrical stimulation was 
adrenergic in origin, the following experiments were performed. After obtaining 
control responses to electrical stimulation, the ovarian vascular bed was perfused with 
KH-solution containing 6-OHDA (10^M) (Karaki et al., 1988b) for 30 min and then 
perfusing with normal KH-solution (i.e. 6-OHDA free) for another 30 min before 
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Fig. 14 Vasodilator and vasoconstrictor responses of the perfused rabbit ovarian 
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Fig. 15 Vasoconstrictor response of the ovarian vascular bed to electrical stimulation, (a) 
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Fig. 16 Vasoconstrictor response of the perfused rabbit ovarian vascular bed to electrical 







Fig. 17 A typical trace of the electrically stimulated perfused rabbit ovarian vascular bed at optimum conditions.
KH-solution to prevent oxidation. As shown in Figure 18a, the response to electrical 
stimulation was abolished after treatment with 6-OHDA. Tyramine-induced 
vasoconstriction was also abolished (Fig. 18b).
3.2 Influence of the endothelium
3.2.1 Effects of endothelial cell removal on agonist-induced responses
In all cases, perfusion with CHAPS (4.7 mg/ml) produced a small elevation in the 
basal perfusion pressure. To confirm that perfusion with CHAPS did remove the 
endothelium, vasodilator responses to carbachol (on preparations pre-constricted with 
NA) were tested before and after treatment with CHAPS. There was an attenuation of 
carbachol-induced responses after CHAPS, confirming loss of the endothelium (Fig. 
19). Endothelium removal with CHAPS had no effect on the vasoconstrictor 
responses to low doses of NA, but there was a significant depression (p < 0.01) of the 
responses to high doses of NA (ED50 = 17.5 nmoles before vs. 7.2 nmoles after 
treatment with CHAPS, maximum response was 100% & 54.6% respectively) (Fig. 
20a). Because CHAPS (4.7 mg/ml) reduced the response to NA at higher 
concentrations, some experiments were carried out using a lower concentration of 
CHAPS (3.0 mg/ml). The results showed that this concentration of CHAPS did not 
affect NA-induced pressor effects, neither did attenuate carbachol-induced relaxation. 
A concentration of 4.7 mg/ml was therefore used in all experiments involving 
denudation of the endothelium.
In order to determine whether the reduced vasoconstrictor effect of NA, following 
treatment of the ovarian vascular bed with CHAPS, resulted from non-specific tissue 
damage, vasoconstriction to KC1 before and after CHAPS treatment was also 
examined. The ovarian vascular bed was perfused with 80 mmoles KC1 solution 
before and after CHAPS. The results summarized in Figure 20b, show that the 
vasoconstrictor effect of KC1 was not affected by pretreatment with CHAPS.
3.2.2 Effects of NOS inhibitors on NA-induced vasoconstriction
3.2.2.1 Effects of L-NOARG and D-NOARG on NA-induced vasoconstriction 
L-NOARG (lO^M-lO^M) alone did not alter the basal perfusion pressure. However, 
L-NOARG significantly (p < 0.05) potentiated the vasoconstricting effect of NA, 
which was only significant at 10'5M (ED50 = 25.1±6.0 & 9.8+0.7 nmoles and
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Fig. 18 Vasoconstrictor response of the perfused ovarian vascular bed to (a) electrical 
stimulation and (b) tyramine; (1) before and (2) after 6-OHDA (lO^M). Perfusion 
pressure was raised with NA (10‘5 M). (* * * p < 0.001)
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Fig. 19 A typical trace of carbachol-induced vasodilatation (a) before and (b) after 
removal of the endothelium (with CHAPS) in the perfused rabbit ovarian vascular bed.
[• represents 1000 nmoles carbachol]
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Fig. 20a NA-induced vasoconstriction in the perfused rabbit ovarian vascular bed 
before (O) and after ( • )  treatment with CHAPS, 4.7 mg/ml for 30 sec (mean±se, n=4). 
Fig. 20b KCl-induced vasoconstriction in the perfused rabbit ovarian vascular bed (a) 
before and (b) after treatment with CHAPS 4.7 mg/ml for 30 sec (mean±se, n=5).
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maximum response was 100% & 126.8% before and after treatment with 10‘5M L- 
NOARG, respectively). Maximum potentiation was observed at a concentration of 
10'5M (Fig. 21a). However, D-NOARG (10’5M and 10“4M) did not increase the 
vasoconstrictor response to NA, in fact it inhibited them. Both concentrations of D- 
NOARG were equi-effective (Fig. 21b).
The response to NA was not affected by incubation with L-NOARG (10'5M) after 
endothelium removal with CHAPS (Fig. 22).
L-Arginine (5x 1 O^M) partially reversed the potentiating effect of L-NOARG (10'5M) 
on NA-induced vasoconstriction (Fig. 23).
3.2.2.2. Effects of aminoguanidine on NA-induced vasoconstriction
Aminoguanidine (10*5M and lO^M) did not affect the basal perfusion pressure of the 
ovarian vascular bed on the NA-induced vasoconstrictor responses in endothelium- 
intact (Fig. 24) or endothelium-denuded preparations.
3.2.3 Effects of NOS inhibitors on agonist-induced vasodilator responses 
Carbachol (1-lOOOnmoles), isoprenaline (l-1000nmoles) and SNP (l-1000nmoles) 
produced reproducible dose-dependent vasodilator responses in the perfused rabbit 
ovarian vascular bed in which perfusion pressure was raised with NA, 10’5M. 
Addition of L-NOARG (10’5M) further increased the perfusion pressure, consistent 
with inhibition of NO synthase activity. At this concentration (10'5M) however, L- 
NOARG did not significantly affect the vasodilator responses of carbachol in about 
60% of the experiments (Fig. 25), while in the remainder of experiments there was a 
reduction in the vasodilator response (p < 0.05). A dose response curve for the overall 
response to carbachol after L-NOARG (10’5M) is shown in Figure 26. On the other 
hand, vasodilator responses to SNP and isoprenaline were maintained after treatment 
with L-NOARG (10'SM).
3.2.4 Effects of cyclicGMP inhibition on agonist-induced vasodilator reponses
Relaxant responses to carbachol were significantly inhibited after perfusion with 
methylene blue (3xl0'5 M) (p < 0.01) or LY 83583 10'5M (p < 0.001) (Fig. 27a). 
However, the relaxant responses to SNP and isoprenaline (1000 nmoles) were not 
significantly affected by LY 83583 (Fig. 27b). Methylene blue, another cyclicGMP 
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Fig.21 Effect of (a) L-NOARG and (b) D-NOARG on NA-induced vasoconstriction in 
the perfused rabbit ovarian vascular bed; control (O), 1 O^M ( • ) ,  10'5M (A) and 1 O^M 
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Fig.22 Effect of L-NOARG 10‘5M ( • )  on NA-induced vasoconstriction (O) in the 
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Fig. 23 Effect of L-arginine on L-NOARG-induced potentiation of vasoconstrictor 
responses to NA in the perfused rabbit ovarian vascular bed (mean+se, n=4-5).
(O) control, ( • )  with L-NOARG (10*5M) and (A) with L-NOARG (10'5M) & L- 
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Fig. 24 Effect of aminoguanidine 10"5M (• )  and lO^M (A) on NA-induced 
vasoconstriction (O) in the perfused rabbit ovarian vascular bed (mean±se, n=5).
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10 4 mi n
Fig. 25 A typical trace of carbachol-induced vasodilatation (a) before and (b) after L 
NOARG (10*5 M). Perfusion pressure was raised with NA (10‘5 M).
[4* represents 1,10 & 100 nmoles carbachol]
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Fig. 26 Vasodilator responses to carbachol, sodium nitroprusside and isoprenaline 
before (O) and after ( • )  L-NOARG (10"5M) in the perfused rabbit ovarian vascular bed 
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Fig. 27a Carbachol-induced vasodilatation before (O) and after ( • )  LY 83583 (10‘5M) 
in the perfused rabbit ovarian vascular bed (mean+se, n=3). ( * * * p < o.OO 1)
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Fig. 27b A typical trace of vasodilator responses to 100 nmoles of (•) carbachol, (*) 
isoprenaline and (T ) sodium nitroprusside in the perfused rabbit ovarian vascular bed, 
(a) before and (b) after incubation with LY 83583 (10‘5M). Perfusion pressure was 
raised with NA 10’5M.
However, SNP-induced vasodilatation was not inhibited, but rather potentiated after 
treatment with a similar concentration of methylene blue (Fig. 28).
3.3 Identification and characterization of adrenoceptors
3.3.1 Identification of adrenoceptors
Phentolamine (10'6) did not affect the basal perfusion pressure of the ovarian 
vascular bed. However, at this concentration, phentolamine antagonized NA- 
induced vasoconstriction. There was a concentration-dependent right-ward shift of 
the NA dose-response curve (p < 0.001) (Fig. 29), with a pKB value of 7.7±0.08.
3.3.2 Effects of adrenergic agonists on perfusion pressure of the ovarian 
vascular bed
Since phentolamine is not selective for a r  or a 2-adrenoceptors, experiments were 
carried out to characterize the subtype of a-adrenoceptors involved in NA-induced 
pressor responses. NA (1 - 1000 nmoles), phenylephrine (10 - 10000 nmoles), 
methoxamine (10 - 10000 nmoles), SDZ NVI 085 (1-1000 nmoles) and 
oxymetazoline (1 - 1000 nmoles) produced concentration-dependent increases in 
perfusion pressure of the ovarian vascular bed. Relative to NA; phenylephrine, 
methoxamine, SDZ NVI 085 and oxymetazoline were partial agonists. Tizanidine 
(10 - 10000 nmoles), clonidine (1 - 1000 nmoles), B-HT 920 (0.1-1000 nmoles) and 
UK 14, 304 (1 - 10000 nmoles) did not increase the perfusion pressure (Fig. 30), 
even after raising the basal perfusion pressure with NA (10"5M).
Unlike the other agonists, oxymetazoline-induced vasoconstriction developed more 
slowly and was more persistent giving a 'spread out' type of response (Fig. 31). 
ED50 and intrinsic activity values are shown in Table 5. Isoprenaline (1-3000 
nmoles) produced a little vasoconstrictor response in some of the preparations (2 out 
of 7). However, when the tone of the ovarian vascular bed was raised with 10 M 
methoxamine (or 10‘5M NA), isoprenaline produced a vasoconstrictor response (in 
all the preparations) at lower doses (3-30 nmoles), and a relaxant effect was 
observed at higher doses ( > 30 nmoles) (Fig. 32). The maximum fall in perfusion 
pressure produced by isoprenaline was 52.4%. This relaxant effect was not inhibited 
by propranolol (lO^M) (Fig. 33). The relaxant response to isoprenaline was found 
to be maintained even when the concentration of propranolol was increased to
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Fig. 28 Vasodilator responses to carbachol and sodium nitroprusside; (0) before and 
( • )  after methylene blue (3x10 5M) in the perfused rabbit ovarian vascular bed 
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Fig. 29 Effect of phentolamine (10‘6M) on NA-induced vasoconstriction in the 
perfused rabbit ovarian vascular bed (mean±se, n=4). (O) control, and ( • )  after
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Fig. 30 Vasoconstrictor effects of some adrenergic agonists on the perfused rabbit 
ovarian vascular bed (mean±se, n=5).
(O) NA, ( • )  phenylephrine, (A) methoxamine, (A) oxymetazoline, (T ) SDZ NVI 085, 
(■) clonidine, tizanidine, B-HT 920 & UK 14 304.
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Fig. 31 A typical trace of (a) oxymetazoline- and (b) NA-induced vasoconstriction in 
the perfused rabbit ovarian vascular bed.
[ 4s represents 3,10, 30,100 and 300 nmoles in ascending order]
Table 5 ED50 and Emax values of some adrenergic agonists in the perfused 
rabbit ovarian vascular bed, (mean±se, n=5). 
a- no vasoconstriction.
b- expressed as a fraction of noradrenaline maximum.
Agonist ED50(nmoles) Emaxb




SDZ NVI 085 193.1±36.4 0.74
Isoprenaline a a
UK 14304 ' a a
Clonidine a a
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Fig. 32 Dose-response curves to NA (O) and isoprenaline ( • )  in the perfused rabbit 
ovarian vascular bed, (A) is response to isoprenaline after raising the perfusion pressure 
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Fig. 33 Vasodilator effect of isoprenaline on the perfused rabbit ovarian vascular bed 
(O) before and ( • )  after treatment with propranolol (lO^M); perfusion pressure was 
raised with methoxamine (10'5M ), (mean±se, n=4).
10.000 100.000 1000.000 10000.01 .0 0 00 0
Isoprenaline (nmoles)
78
3 710‘ M. In some experiments, perfusion pressure was raised with U46619 (3x10 M) 
or histamine (10'5M). Under these conditions, isoprenaline produced vasoconstrictor 
responses at all doses. These vasoconstrictor responses were attenuated by 
phentolamine (lO^M) (Fig. 34).
3.3.3 Effects of prazosin and yohimbine on agonist-induced vasoconstriction
8 5Prazosin (10" - 10" M) did not affect the basal perfusion pressure of the ovarian 
vascular bed. At these concentrations, however; prazosin antagonized NA-induced 
vasoconstriction. There was a concentration-dependent rightward shift of the NA 
dose-response curve with no suppression of the maximum response (Fig. 35). The 
Schild plot was monophasic with a slope of 1.0±0.1 indicating competitive 
antagonism. The pA2 value was 7.35±0.3. Prazosin also produced a concentration- 
dependent rightward shift of phenylephrine and oxymetazoline dose-response 
curves (Fig. 35). The Schild plots for phenylephrine and oxymetazoline were 
monophasic with slopes of 1.1±0.1 and 0.96±0.04 respectively, indicating 
competitive antagonism. The pA2 values calculated for prazosin against 
phenylephrine and oxymetazoline were 7.27±0.1 and 6.38±0.2 respectively. 
Concentrations of prazosin greater than 3xlO’7M significantly suppressed the 
maximum response to methoxamine and SDZ NVI 085. Therefore, KB values were 
determined for prazosin using 3xlO‘7M as the antagonist concentration. Prazosin 
produced a significant shift (p<0.01) of the methoxamine and SDZ NVI 085 dose- 
response curves to the right (Fig. 36). The pKB values were calculated to be 
7.7±0.28 and 7.4±0.2 against methoxamine and SDZ NVI 085 respectively 
(Table 6).
Yohimbine at concentrations up to 10*5M did not alter the basal perfusion pressure 
of the ovarian vascular bed. At the lower concentrations (10’7M and lO^M), 
yohimbine did not antagonize NA-induced vasoconstriction, while at 10’5M, it 
produced a parallel nonsignificant rightward shift of the NA dose-response curve 
with no reduction in the maximum response (Fig. 37). The pKB was 7.1(±2.2)xl0‘6. 
Thus the prazosin / yohimbine ratio was 112.2.
Yohimbine at concentrations of lO^M-lO^M caused a leftward shift of the 
phenylephrine dose-response curve (Fig. 37). The more significant shift was 
observed at yohimbine 10’5 M, where the pKB value was found to be 5.7±0.2.
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^Histamine 'fcHistamjne
Fig. 34 A typical trace o f  isoprenaline-induced vasoconstriction after raising the basal 
perfusion pressure with histamine 10‘5M, (a) before and (b) after incubation with 
phentolamine lO^M.




0.100 1.000 10.000 100.0001000.00 10000.0 100000.0 









100000.0100 1000 10000.01 10
120
P h e n y l e p h r i n e  ( n m o l e s )
0.100 1.000 10.000 100.000 1000.000 
O x y m e t a z o f i n e  ( n m o l e s )
Fig. 35 Effect of prazosin on NA-, phenylephrine- and oxymetazoline-induced
vasoconstriction in the perfused rabbit ovarian vascular bed (mean±se, n=5). (O)
control, ( • )  10-* M, (A) 10'7 M, (V) 3xl0'7 M, (A) lO'4 M, (T) 3x10^ M and 10'SM (0 )
(mean±se, n=5-6). All values starting hum 1000 nmoles are extremely significant at
antagonist concentrations of 10"6 M, 3x 1 O'6 M and 1 O’5 M.
(* p < 0.05, ** p < 0.01 & *** p < 0.001)
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Fig. 36 Effect o f prazosin 3xlO‘7M ( • )  on methoxamine- and SDZ NVI 085-induced 
vasoconstriction (O) in the perfused rabbit ovarian vascular bed (mean±se, n=5-6).
(* p < 0.05, ** p < 0.01 & *** p < 0.001)
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Table 6 Antagonist potencies of prazosin in the perfused rabbit ovarian 
vascular bed, (mean±se, n=5). 







SDZ NVI 085 7.4±0.2
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Fig. 37 Effect o f yohimbine, 10‘7M ( • ) ,  1 (A) and 10’5M (A ) onNA- and
phenylephrine-induced vasoconstriction (O) in the perfused rabbit ovarian vascular bed
(mean±se, n=4).
84
3.3.4 Effects of a-adrenoceptor antagonists on electrically-induced 
vasoconstriction
7 5Prazosin (10 M-10 M) produced a significant concentration-dependent reduction of 
the electrically-induced vasoconstrictor responses (pO.OOl). However, the effect 
of yohimbine (10‘7M-10'5M) was not significant (p>0.05) (Fig. 38) At the highest 
concentration used (10’5M), yohimbine reduced the response to electrical stimulation 
by only 15%.
3.3.5. Effects of subtype-selective o^-adrenergic antagonists on agonists-
induced vasoconstiction
3.3.5.1 Competitive antagonists
None of the concentrations of WB-4101 used in this study altered the basal
8 5perfusion pressure of the ovarian vascular be. WB-4101 (10* - 10" M) produced 
dose-dependent parallel rightward displacement of NA dose-response curve. There 
was no reduction in the maximum response (Fig. 39). The Schild regression line 
was a straight line having a slope of 1.0±0 .1, indicating competitive antagonism. 
The pA2 value was 7.9±0.2 (Table 7). WB 4101 also produced concentration- 
dependent parallel rightward displacements of phenylephrine and oxymetazoline 
dose-response curves without a significant reduction in the maximum response (p > 
0.05) (Fig. 39). The Schild plot for the two agonists were straight lines with slopes 
of 0.85±0.1 and 0.86±0.1 respectively. These values were not significantly different 
from 1.0, indicating competitive antagonism. The pA2 values were 7.3±0.2 and 
6.9±0.4 respectively. As with prazosin, concentrations of WB-4101 greater than
n
3x10* M reduced the maximum response to methoxamine and SDZ NVI 085. 
Therefore, only one concentration of WB-4101 (3xlO‘7M) was used to determine 
pKB values. As shown in Figure 40, WB-4101 produced a rightward shift of the 
dose-response curves to methoxamine and SDZ NVI 085. The pKB values were 
calculated to be 7.1±0.3 and 7.7±0.1 respectively. Niguldipine (10*9M) produced a 
highly significant rightward displacement of the NA dose-response curve (p < 0 .001) 
(Fig. 41).
8 7WB-4101 (3x10* M-3xl0* M) produced a significant concentration-dependent 
suppression of the electrically induced vasoconstrictor response (p < 0.001) (Fig. 
42).
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Fig. 38 Effect o f (a) prazosin and (b) yohimbine on the response of the perfused rabbit 
ovarian vascular bed to electrical stimulation (mean±se, n=4).
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Fig.39 Effect of WB-4101 on NA-, phenylephrine- and oxymetazoline-induced 
vasoconstriction in the perfused rabbit ovarian vascular bed (mean±se, n=5).
(O) control, WIO^M, ( • )  10'7M, (A) 3xlO'7M, (A) lO^M, (□) 3x1 O^M and (V) 
10*5M. [For NA, phenylephrine and oxymetazoline, all values starting from 10, 1000 
and 100 nmoles respectively, are extremely significant starting at antagonist 
concentration of 1 O'* M] (* p < 0.05 & * * p < 0.01)
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Table 7 Antagonist potencies of WB-4101 in the perfused rabbit ovarian vascular 








SDZ NVI 085 7.7±0.1
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Fig. 40 Effect of WB_4101 3x10'7M ( • )  on methoxamine- and SDZ NVI 085-induced 
vasoconstriction (O) in the perfused rabbit ovarian vascular bed (mean±se, n=5-6).
(* p < 0.05 & *** p <0.001)
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Fig. 41 Effect o f niguldipine, lO^M ( • )  on NA-induced vasoconstriction (O) in the 


















Fig. 42 Effect of WB_4101 on the response of the perfused rabbit ovarian vascular bed 




CEC QxlO^M-lO^M) did not alter basal perfusion pressure of the ovarian vascular 
bed. At these concentrations, CEC did not reduce NA-induced vasoconstriction. 
Instead, it produced a slight but not significant leftward shift of the NA dose 
response curve (p > 0.05). At a concentration of (104M), CEC did not reduce the 
oxymetazoline-induced vasoconstriction (Fig. 43).
SZL-49 (5x1 O^M) did not alter the basal perfusion pressure of the ovarian vascular 
bed. But at this concentration, SZL-49 (5x1 O^M) displaced significantly (p < 0.05) 
the NA-dose response curve to the right (fig. 44). Moreover, SZL-49 (5x1 O^M) 
produced a rightward shift (p < 0.05) of the agonist dose-response curves, 
phenylephrine, oxymetazoline, methoxamine and SDZ NVI 085 ( Figs. 44 & 45). 
There was no reduction in the maximum response to any of the agonists.
SZL-49 (5x1 O^M) significantly reduced the vasoconstrictor response to electrical 
stimulation (p<0.001), while CEC (lO^M) had no significant effect (p > 0.05) (Fig. 
46).
3.4 Signal transduction mechanisms
3.4.1 Calcium-free solution
2 +
Incubation of the ovarian vascular bed in Ca -free KH solution did not alter the
basal perfusion pressure. However, there was a highly significant reduction in the
2+NA-induced vasoconstriction (p < 0.001). In this Ca -free medium, the dose- 
response curve was shifted to the right and the maximum response to NA was 
reduced to approximately 15% of the control (Fig. 47). Addition of EGTA 
(2mM) to the solution abolished the residual response to NA. As shown in Figure 
48, there was a time-dependent loss of NA-induced vasoconstriction when the 
ovarian vascular bed was perfused with Ca2+-free KH-solution. The response to NA 
(300 nmoles) was reduced by approximately 60% within the first 5min of perfusion 
with KH-solution and less than 5% after 45min. The half life for the loss of
responsiveness to NA was found to be 4 min. Addition of EGTA (2mM) to the
2+
Ca -free KH-solution accelerated the loss of vasoconstrictor effect (Fig. 49). Under 
these conditions, vasoconstrictor effect of NA was reduced by approximately 90% 
within 5min and by 15min the response was abolished. The half life for the loss of
92
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Fig. 43 Effect of CEC, 3x10 5M ( • )  and 10"*M (A) on NA- and oxymetazoline-induced 
vasoconstriction (O) in the perfused rabbit ovarian vascular bed (mean±se, n=4).
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Fig. 44 Effect of SZL-49, 5x1 O^ M ( • )  on NA-, phenylephrine- and oxymetazoline-
induced vasoconstriction (O) in the perfused rabbit ovarian vascular bed (mean±se,
n=4-5). (* p < 0.05, ** p < 0.01 & *** p < 0.001)
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Fig. 45 Effect o f SZL-49, 5x1 O^M ( • )  on methoxamine- and SDZ NVI 085-induced 
vasoconstriction (0 ) in the perfused rabbit ovarian vascular bed (mean±se, n=5).
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Fig. 46 Vasoconstrictor response of the perfused ovarian vascular bed to electrical 
stimulation (1) before and (2) after irreversible antagonists; (a) SZL-49 5x1O^M and (b) 
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Fig. 47 Effect of Ca2+-ffee KH-solution with (A) or without ( • )  EGTA on NA-induced 
vasoconstriction (O) in the perfused rabbit ovarian vascular bed (mean±se, n=4).
(* p < 0.05, ** p < 0.01 & p < 0.001)
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30 min
0-Ca2+ KH-solution Normal KH-solution
10 4 min
Fig. 48 A typical trace of time-dependent loss of NA-induced vasoconstriction (• = 300 
nmoles NA) in Ca2+-free KH-solution.
CO GO
Fig. 49 Time-dependent loss o f NA-induced vasoconstriction in Ca2+-ffee KH-solution, 
with (b) or without (a) EGTA (2mM) (mean±se, n=6).
[after 5 min (1), 15 min (2), 30 min (3) & 45 min ^)] (*** p < 0.001)
99
responsiveness to NA was 2.5 min.
3.4.2 Calcium channel blocking agents
Neither verapamil nor nifedipine, modified the basal perfusion pressure of the
*7
ovarian vascular bed. Verapamil (10‘ M) significantly reduced the response to 
higher doses of NA (>30 nmoles). Hence, as shown in Figure 50, there was no 
rightward displacement of the NA-dose response curve. Increasing the 
concentrations of verapamil to lO^M did not result in increased blockade of NA 
response. However, at 10'5M, verapamil produced a reduction in the response to 
NA. At this concentration, verapamil reduced the vasoconstrictor response to low 
and high doses of NA.
8 5Similarly, nifedipine at concentrations of (10' M-10' M) produced a shift of the 
dose-response curve to NA accompanied by a reduction in the maximal response. 
The reduction was only statistically significant at the high doses of NA (p<0.05) 
(Fig. 50).
SDZ NVI 085-induced vasoconstriction was affected in a concentration dependent 
manner by verapamil and nifedipine. The reduction in the contractile response was 
observed at the higher concentrations of the inhibitors (Fig. 51) However, 
vasoconstrictor responses to low doses of SDZ NVI 085 were significantly reduced 
by verapamil and nifedipine.
In another set of experiments, the effects of verapamil and nifedipine on KC1- 
induced vasoconstriction were examined. The KCl-induced vasoconstriction was 
significantly (p<0.001) reduced by verapamil and nifedipine (Fig. 52).
3.43 Intracellular calcium antagonist
Perfusion of the ovarian vascular bed with KH-solution containing ryanodine 10"5M 
did not affect the basal perfusion pressure of the preparations. Neither did it produce 
any significant change in response to NA (p > 0.05) (Fig. 53).
3.4.4 Protein kinase C inhibitors
HA-1077 (3x10’7M) produced a significant suppression (p < 0.01) o f maximal 
response to NA. A further significant reduction in response to NA was observed at 
3x1 O^M (p<0.05) (Fig. 54). However, polymyxin B (lO^M-lO^M) did not cause 
any significant reduction in the pressor response to NA (p > 0.05). There was a 
slight but non-significant enhancement of NA dose-response curve at concentrations
100
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Fig. 50a Effect o f verapamil 10'7M ( • )  , lO^M (A) and 10'5M (A ) on NA-induced 
vasoconstriction (O) in the perfused rabbit ovarian vascular bed (mean±se, n=4).
Fig. 50b Effect o f nifedipine lO^M ( • ) ,  10‘7M(A), 10^M (▲) and 10‘5M (□) on
NA-induced vasoconstriction (O) in the perfused rabbit ovarian vascular bed (mean±se, 
n=4). (* p < 0.05, ** p < 0.01 & *** p < 0.001)
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Fig. 51 Effect of (a) verapamil and (b) nifedipine; 10'8M ( • ) ,  10'7M (A), lO^M (A ) and 
10-5M (□) on SDZ NVI 085-induced vasoconstriction (O) in the perfused rabbit 
ovarian vascular bed (mean±se, n=4). [vasoconstrictor effects to SDZ NVI 085 > 1 0  
nmoles are significant at concentrations of 10 '7 M, 10"6 M & 10 ‘5 M o f verapamil & 
nifedipine, p < 0.01]
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Fig. 52 Effect o f verapamil (a) and nifedipine (b); 10‘8M (1), 10'7M (2) and 10“^  (3) 
on KCl-induced vasoconstriction in the perfused rabbit ovarian vascular bed (mean±se, 
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Fig. 53 Effect of ryanodine, 10*5M (#)on NA-induced vasoconstriction (O) in the 
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Fig. 54 Effect of HA-1077 3xlO'7M ( • )  and 3x1 O^ M (A) on NA-induced 
vasoconstriction (O) in the perfused rabbit ovarian vascular bed (mean±se, n=4).
(♦ p < 0.05, **p< 0.01 & ***p< 0.001)
105
of lO^M-lO^M. (Fig. 55). As shown in Figure 56, vasoconstrictor response to 
CaCl2 (100 jiM) was significantly attenuated after treatment with HA-1077 (p < 
0.05), while responses were not affected by polymyxin B, even at the concentration 
of lO^M.
3.4.5 Tyrosine kinase inhibitor
Incubation of the ovarian vascular bed with genistein (lO^M-lO^M) produced a 
significant (p < 0 .01) suppression of the NA dose-response curve accompanied by a 
reduction of the maximal response (Fig. 57).
3.5 Effects of hormones and pregnancy
3.5.1 Ovulation induction with HCG
In this group of rabbits, the isolated ovaries were reddish and swollen, indicating 
increased permeability and blood supply. Ovulation points (follicles) observed were 
6.7±0.8 in a group of 6 rabbits. The basal perfusion pressure for HCG-treated 
rabbits was 27.5 ± 5.3 mmHg. This was significantly (p < 0.05) different from 
corresponding values in control rabbits (Table 8). NA and oxymetazoline produced 
dose-dependent vasoconstriction of the ovarian vascular bed (Fig. 58). The ED50 
values were 4.5±1.4 and 3.8±1.7 nmoles respectively. These values were 
significantly lower than corresponding values obtained for NA (p < 0.05) and 
oxymetazoline (p < 0.05) in control rabbits (Table 9) indicating enhanced sensitivity. 
In order to determine whether the increased sensitivity of the ovarian vascular bed to 
NA and oxymetazoline was due to a specific alteration in a!-adrenoceptor sensitivity 
or a non-specific increase in tissue sensitivity, the pressor effect of histmine was 
examined. As shown in Figure 59, the sensitivity of the preparations to histamine 
was not altered by HCG treatment. The ED50 values were 51.9±5.4 and 53.5±9.0 in 
control and HCG treated rabbits respectively (p > 0.05). The maximum increases in 
perfusion pressure recorded for NA, oxymetazoline and histamine (Table 10) were 
not significantly different between control and HCG treated rabbits (p > 0.05). 
Oxymetazoline remained as a partial agonist.
The vasoconstrictor responses to NA were slightly but not significantly (p > 0.05) 
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Fig. 55 Effect of polymyxin B 1 0 ^  (•) , 10‘5M (A) and lO^M (▲) on NA-induced 




Fig. 56 Vasoconstrictor responses to CaCl2 (100 pmoles) in 80 mM KC1 depolarized 
KH-solution before and after treatment with PKC inhibitors (mean±se, n=3).
(a) HA-1077, (1) 3xl0'7 M and (2) 3x10^ M.
(b) Polymyxin B , (1) 10"6 M, (2) 10'5 M and (3) 10"4 M.
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Fig. 57 Effect of genistein, lO^M ( • )  and 10’5M (A) on NA-induced vasoconstriction 
(O) in the perfused rabbit ovarian vascular bed (mean±se, n=4).
(♦ p < 0.05, *♦ p < 0.01 & *** p < 0.001)
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Table 8 Basal perfusion pressures (B.P.P. mmHg), o f the perfused 
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Fig. 58 NA- (O) and oxymetazoline-induced vasoconstriction ( • )  in the perfused 
ovarian vascular bed of HCG-treated (100 i.u.) rabbits (mean±se, n=5).
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Table 9 ED50 values (nmoles) for different agonists in the perfused ovarian 
vascular bed of control and treated rabbits, (mean ±  se, n=4-8).
(* = p<0.05 & ** = p<0.01)
NA Oxymetazoline Histamine
Control 25.1±6.0 53.4±15.6 51.9±5.4
HCG-treated 4.5±1.4** 3.8±1.7* 53.5±9.0
Oestrogen-treated 14.7±5.3 3.3±1.8* 45.4±7.8
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Fig. 59 Histamine-induced vasoconstriction in the perfused ovarian vascular bed of 
control (O) and HCG-treated (100 i.u.) rabbits ( • )  (mean±se, n=4). ( ** p < 0.01)
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Table 10 Maximal increases in perfusion pressure (mmHg) produced by 
different agonists in the perfused ovarian vascular bed of control and treated 
rabbits, (mean ±  se, n=4-8).
(* = p<0.05)
Noradrenaline Oxymetazoline Histamine
Control 198.8±11.2 135.4±12.2 205±18.7
HCG-treatad 206.7±14.0 176.3±13.3 171.9±29.7
Oestrogen-treated 214.6±10.9 187.0+16.1* 181.3±10.1
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Fig. 60 Effect of L-NOARG 10~5M ( • )  on NA-induced vasoconstriction (O) in the 
perfused ovarian vascular bed of HCG-treated (100 i.u.) rabbits (mean±se, n=4).
115
Relaxant responses for carbachol and SNP were established before and after 
incubation with L-NOARG. Carbachol (0.1-1000 nmoles) dose-dependently 
reduced the perfusion pressure. The ED50 value of carbachol was 8.4±3.9 nmoles 
and the maximum relaxation was 42.6±11.3 % of basal tone. Carbachol-induced 
relaxation was suppressed significantly after incubation with L-NOARG 10'5M 
(p<0.05). SNP (0.1-1000 nmoles) also produced a dose-dependent reduction in 
perfusion pressure. However, L-NOARG (10'5M) had no effect on SNP-induced 
responses (Fig. 61) (Table 11). There was no significant difference in ED50 values 
or maximal relaxation produced by carbachol or SNP in the control and HCG-treated 
rabbits (p > 0.05).
3.5.2 Effects of 17-15-oestradiol
The basal perfusion pressure in the ovarian vascular bed isolated from oestrogen- 
treated rabbits was 33.0 ±3 .4  mmHg, which was not significantly different from 
corresponding values in control rabbits (p > 0.05). NA and oxymetazoline produced 
dose-dependent vasoconstriction of the ovarian vascular bed (Fig. 62). The ED50 
values were 14.7±5.3 and 3.3±1.8 nmoles respectively. These values were lower 
than those in control rabbits. The ED50 value for oxymetazoline was significantly 
reduced (p < 0.05), indicating enhanced sensitivity. The sensitivity of the 
preparations to histamine was not affected (ED50 values were 51.9±5.4 and 45.4±7.8 
nmoles in control and oestrogen-treated rabbits, respectively). There was no 
significant difference in the maximum perfusion pressures recorded for NA or 
histamine in control and oestrogen treated rabbits, while the corresponding value for 
oxymetazoline was significantly enhanced (p < 0.05) (Table 10). Vasoconstrictor 
responses to NA were not significantly potentiated by L-NOARG (10‘5M) (Fig. 63). 
Carbachol (0.1-1000 nmoles) produced a dose-dependent reduction in perfusion 
pressure. At the highest concentration of cabachol used, the reduction in pressure 
was41.7±8.4% of basal tone. The ED50 value was 3.3±0.2 nmoles. The relaxant 
response to carbachol was significantly reduced after incubation with L-NOARG 
10’5M (p < 0.01). SNP also produced a dose-dependent reduction in perfusion 
pressure. However, the response to SNP was not affected by L-NOARG 10'5M. 
There was no significant difference in ED50 values or maximal relaxation produced 
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Fig. 61 Effect of L-NOARG 10'5M ( • )  on vasodilator responses to (a) carbachol and
(b) sodium nitroprusside in the perfused ovarian vascular bed of HCG-treated (100 i.u.) 
rabbits (mean±se, n=4). (* p <  0.05)
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Table 11 ED50 values and maximal reduction in perfusion pressures for carbachol 
and SNP in the perfused ovarian vascular bed of control and treated rabbits, 
(mean±se, n=4-5). 
a = nmoles
P.P. = perfusion pressure
ED50a
Carbachol
% Reduction P.P. ED50a
SNP
%  Reduction P.P.
Control 3.2±0.9 69±9.5 2.9±1.1 74.4±14.1
HCG-treated 8.4±3.9 42.6±11.3 9.9±5.9 72.0±12.5
Oestrogen-treated 3.3±0.2 41.7±8.4 6.3±1.2 81.0±4.2
Pregnant
. . .
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Fig. 62 NA- (O) and oxymetazoline-induced vasoconstriction ( • )  in perfused ovarian 
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Fig. 63 Effect of L-NOARG 10*5M (• )  on NA-induced vasoconstriction (O) in the 
perfused ovarian vascular bed of B-oestradiol 17-propionate-treated (5 mg) rabbits 
(mean±se, n=4).
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NA-induced vasoconstriction was not affected at lower concentrations of 17-B- 
oestradiol, when applied to the perfusing medium. However, at higher 
concentrations of 17-B-oestradiol, NA-induced vasoconstriction was attenuated (Fig. 
64). In addition, there was a significant suppression in the maximal perfusion 
pressure (p < 0 .001).
3.5.3 Effects of pregnancy
The mean basal perfusion pressure for the ovarian vascular bed in pregnant rabbits at 
day 22 - 24 of gestation was 27.8 ± 4.1 mmHg and this was significantly different (p 
< 0.05) from corresponding values in control rabbits. NA and oxymetazoline 
produced dose-dependent vasoconstriction of the ovarian vascular bed (Fig. 65). 
The ED5o values were 10.0+3.0 and 6.2±2.0 nmoles respectively. These values were 
significantly lower (p < 0.05) than corresponding values obtained for NA and 
oxymetazoline in control rabbits (Table 9), indicating that sensitivity to these agents 
was enhanced. The sensitivity of the preparations to histamine was significantly 
reduced during pregnancy (p < 0.01) (Fig. 66). The ED50 values were 51.9±5.4 and 
147.4±24.4 nmoles in control and pregnant rabbits respectively. The maximum 
perfusion pressures recorded for NA and histamine were not significantly different 
compared to control animals (p > 0.05), while the corresponding value for 
oxymetazoline was significantly reduced (p < 0.05) (Table 10). Vasoconstrictor 
responses to NA were not significantly potentiated by L-NOARG 10'5M. TheED50 
value for NA after L-NOARG (10'5M) in the pregnant rabbit was 5.5±2.9 nmoles 
and the maximum response was 87.3%. However, the vasoconstrictor response to 
oxymetazoline was significantly potentiated by L-NOARG (10'5M) (p < 0.05) (Fig. 
67). Yohimbine (10"5M) did not affect the NA dose-response curve (Fig. 68). In 
addition, B-HT 920 did not produce any vasoconstrictor response either at basal 
perfusion pressure or when it was raised with U46619, indicating that a 2- 
adrenoceptors were not functional.
Prazosin (10’7M) shifted the NA dose-response curve without suppressing the 
maximum response (Fig. 69). The pKB value was calculated to be 9.6 ± 0.3. 
Vasoconstrictor responses to NA were not affected after incubation with CEC 
(3x10"5M), however, there was a significant reduction (p < 0.001) after incubation 
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Fig. 64 Effect of 17-B-oestradiol (in vitro) 3xlO*9M (•), 3xlO‘8M (A), 3xlO’7M (A), 
3xlO'6M (□) and 3xlO‘5M (■) on NA-induced vasoconstriction (O) in the perfused 
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Fig. 65 NA- (O) and oxymetazoline-induced vasoconstriction ( • )  in the perfused 
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Fig. 66 Histamine-induced vasoconstriction in perfused ovarian vascular bed of control 
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Fig. 67 Effect of L-NOARG 10'5M ( • )  on (a) NA- and (b) oxymetazoline-induced 
vasoconstriction (b) in the perfused ovarian vascular bed of pregnant rabbits (mean±se, 
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Fig. 68 Effect of yohimbine, 10'5M (• )  on NA-induced vasoconstriction (O) in the 
perfused ovarian vascular bed of pregnant rabbits (mean±se, n=4).
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Fig. 69 Effect of prazosin, 10*7M ( • )  on NA-induced vasoconstriction (O) in the 
perfused ovarian vascular bed of pregnant rabbits (mean±se, n=5).
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Fig. 70 Effect of irreversible antagonists ( • )  on NA-induced vasoconstriction (O) in the 
perfused ovarian vascular bed of pregnant rabbits, (a) CEC 3xlO‘5M & (b) SZL-49 
5xlO**M (mean±se, n=4). (**p<0.01&  ***p< 0.001)
128
Relaxant responses for carbachol and SNP were established before and after 
incubation with L-NOARG. Carbachol (0.1-1000 nmoles) dose-dependently 
reduced the perfusion pressure. The ED50 value of was 7.2±3.9 nmoles and the 
maximum relaxation was 61.0±11.7% of basal tone. Carbachol-induced relaxation 
was suppressed significantly after incubation with L-NOARG 10"5M (p<0.05), while 
SNP-induced responses were not affected (Figs. 71 and 72). There was no 
significant difference in ED50 values or maximal relaxation produced by carbachol 





(a)  ( b )
J  \  I  \  \  I I
* n a
4 min
Fig. 71 A typical trace of carbachol-induced vasodilatation in pregnant rabbits, (a) 
before and (b) after L-NOARG (10‘5 M). Perfusion pressure was raised with NA 
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Fig. 72 Effect of L-NOARG 10'5M (• )  on vasodilator responses to (a) carbachol and 
(b) sodium nitroprusside in the perfused ovarian vascular bed of pregnant rabbits 





The mammalian ovary is well supplied with autonomic nerves of both sympathetic 
and parasympathetic origin (Owman et al., 1979). The nerve terminals innervate 
blood vessels and also form networks around follicles in various stages of 
development. In the follicle walls, they establish close contacts with smooth muscle 
cells in the theca externa layer (Burden, 1978; Owman et al., 1979). Thus the 
adrenergic nerves may play a role in regulating blood flow to the ovary, ovulation and 
also serve a neuroendocrine function. Previous studies have shown that noradrenaline 
evoked dose-dependent vasoconstrictor responses in the rabbit (Graham & Sani, 
1971), human (Varga et al., 1979) and ewe (Kuhl et al., 1974) ovarian artery, but the 
receptors mediating such responses were not analysed. Oriowo and Bevan (1986), 
showed that the a  |-adrenoceptors mediated noradrenaline-induced contractions of ring 
segments of the rabbit ovarian artery. However, there is now evidence in the 
literature, indicating that, events taking place in muscular arteries may not always 
reflect what happens in the resistance vessels. For example, Cauvin et al., (1984) 
showed that the effectiveness of Ca2+ channel antagonists, in inhibiting NA-induced 
contractions was inversely related to the vessel diameter. Thus mesenteric resistance 
vessels are more sensitive to nifedipine than the muscular superior mesenteric artery. 
The difference (i.e. between resistance arteries and muscular arteries) is not limited to 
signal transduction mechanism. It has been shown that both a r  and a 2-adrenoceptors 
are involved in NA-induced contractions of small diameter rabbit intrarenal arteries 
(Owen & Patel, 1994; 1996). In contrast, only aj-adrenoceptors mediated NA- 
induced contraction of the main renal artery (Oriowo et al., 1989). Similarly, while rat 
renal artery responses to electrical stimulation and exogenous a-adrenergic agonists 
are exclusively mediated via a!-adrenoceptors (Schmitz et al., 1981; Wolff et al.,
1987); Bohmann et al, (1995) have uncovered a 2-adrenoceptors, mediating 
vasoconstriction in spontaneously hypertensive rat kidneys in the presence of low 
concentrations of angiotensin II. Thus under certain conditions, a 2-adrenoceptors 
activity could be unmasked. Recent studies have also shown that noradrenaline- 
induced vasoconstriction in the perfused mesenteric vascular bed was resistant to 
inhibition by CEC indicating mediation via a 1A-adrenoceptor subtype. This is in
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contrast to NA-induced contractions of ring segments of the superior mesenteric artery 
which were CEC sensitive indicating a 1B (a1D?) receptors were involved.
Therefore, the main objective of this study was to characterize a-adrenergic receptors 
mediating vasoconstriction in the ovarian vascular bed and how these may be 
influenced by the endothelium and changes in hormonal status following ovulation 
and pregnancy. In addition, experiments were also carried out to identify the signal 
transduction mechanisms involved in the response to adrenergic receptor activation. 
The perfused whole vascular bed preparation is a set-up designed to mimic the in situ 
situation. The perfusion pressure can be controlled and set to the level that can be 
obtained in vivo. Also, the preparation can be perfused at a constant flow rate or 
pressure. Both of these techniques are relevant to in vivo situations. In the present 
study, perfusion at a constant flow rate was the method of choice mainly because 
techniques for studying ovulation, in vitro, using the perfused rabbit ovary utilized a 
constant flow rate approach (Uchida et al., 1967; Lambertsen et al., 1976; Wallach et 
al., 1978; Kobayashi et al., 1981). One disadvantage of this system (i.e. perfused 
whole bed) is that, with time, the perfused vascular bed becomes oedematous which 
could affect the results. For example, in the rat isolated perfused lung preparation, 
there was a time dependent gain in lung weight (oedema) increasing from 6% after 2hr 
to 96% after 4hr of perfusion (Lai et al., 1994). Thus the first set of experiments were 
designed to study the time-dependence of the response of the ovarian vascular bed to 
NA. This was essential since in antagonist studies, each preparation would serve as its 
own control. The results showed that at least 4 consecutive dose-response curves (at 
45-60 min interval) could be obtained in each preparation, without a difference in 
potency or maximum response. There was a significant increase in weight of the 
preparation at the end of the experiment which could be attributed to the fluid trapped 
in the fatty tissue surrounding the ovarian artery close to its point of entry into the 
ovary. It was observed that the more the fat, the more was the gain in weight. This 
oedema, however, had no effect on the basal perfusion pressure which remained 
constant throughout the experiment and therefore, it was a reliable preparation. 
Noradrenaline is the main neurotransmitter in sympathetic nerves and therefore it was 
chosen to be the reference agonist with which other agonists were compared. The 
dominant mechanism terminating the action of NA in sympathatically innervated
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tissues is the uptake process (Iversen & Salt, 1970). This process is inhibited by 
cocaine and tricyclic antidepressants (Hughes, 1972). Later studies have shown that 
influence of the uptake system on NA-induced vasoconstriction is directly 
proportional to the density of innervation (Bevan et al., 1974). Therefore, in the 
present study, failure of uptake blockers (cocaine and DOCA), singly or in 
combination to significantly enhance NA-induced vasoconstriction could be due to the 
low level of adrenergic innervation of the ovarian vasculature (Stefenson et al., 1981). 
The uptake process is also affected by the width of the synaptic cleft. There is 
evidence, showing that the concentration of neurotransmitter in the cleft of medially 
innervated tissues (small width of synaptic cleft) is several fold higher than was found 
in the cleft of junctionally innervated tissues (Bevan, 1977) and this was attributed to 
the fact that diffusion away from the cleft is much higher in junctionally innervated 
tissues. Even though there is no indication of the width of the synaptic cleft in the 
ovarian vasculature, the possibility that diffusion away from the cleft rather than 
uptake into the nerves could be responsible for terminating the action of NA cannot be 
excluded.
The reactivity of an isolated vascular smooth muscle preparation to NA is also 
influenced by a simultaneous activation of B-adrenoceptors and a release of 
prostanoids/EDRF from the endothelium. NA activates B-adrenoceptors, being more 
selective for Bj-adrenoceptor subtype (Lands et al., 1967). Although it was earlier 
assumed that l^-adrenoceptors mediate vasodilatation, it is now known that Br  
adrenoceptor activation can also result in vasodilatation. This has been shown in 
several arterial preparations (Edvinsson & Owman, 1974; Edvinsson et al., 1976; 
Nakane et al., 1988; Yamada et al., 1988; Purdy et al., 1988). Thus a simultaneous 
activation of B-adrenoceptors could limit the response of the arterial smooth muscle to 
NA by a process of physiological antagonism. However, results obtained in this study 
showed that NA-induced vasoconstriction in the ovarian vascular bed was not 
enhanced by blocking B-adrenoceptors with propranolol, indicating that NA-induced 
vasoconstriction in this preparation was not limited by a simultaneous activation of fi- 
adrenoceptors.
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In many vascular smooth muscle preparations, the vasoconstrictor response to NA is 
accompanied by a release of prostanoids including PGF2ot, PGE2 , TXB2 and PGI2 from 
the endothelium and smooth muscle (McGiff et al., 1976; Boeynaems et al., 1987). 
PGF2a and TXB2 are vasoconstrictor agents while PG&, and PGI2 are vasodilators. 
Thus the overall modulatory effect of the prostanoids would depend on the relative 
proportions of dilator and constrictor prostanoids. In the perfused rabbit ovarian 
vascular bed (this study), indomethacin (5x1 O^M) did not affect NA-induced 
vasoconstrictor responses indicating that NA-induced vasoconstriction was not 
modulated by the prostanoids. This could be due to one or both of two possibilities, 
either that the prostanoids were not generated in enough concentrations to produce a 
response or that the effects of vasodilator and vasoconstrictor prostanoids on NA- 
induced vasoconstriction neutralize each other. There is no evidence to support either 
of these alternatives. In subsequent experiments therefore, none of these inhibitors 
(propranolol, indomethacin, DOCA and cocaine) were routinely used.
Transmural electrical stimulation at supramaximal voltage induced a frequency- 
dependent vasoconstriction of the ovarian vascular bed. The response was abolished 
by 6-OHDA indicating that it was adrenergic in nature. However, the vasoconstrictor 
response to electrical stimulation was weak when compared to the maximum response 
to exogenous NA. This is consistent with a sparse adrenergic innervation of the rabbit 
ovarian arteries and low content of NA in the ovarian nerves (Stefenson et al., 1981).
4.2 Influence of the vascular endothelium
In several vascular beds, perfusion with CHAPS is an effective way of removing the 
endothelium. Successful de-endothelialization was evidenced by an increased 
sensitivity to contractile agonists and loss of endothelium-dependent vasodilation 
(Tesfamariam & Halpren, 1987; Moore et al., 1990). This procedure was therefore 
employed to remove the endothelium in the ovarian vascular bed in an attempt to 
assess the influence of the endothelium on vasoconstrictor effects of NA. The 
concentration of CHAPS (4.7 mg/ml) used in this study has been shown to effectively 
remove the endothelium in several vascular beds, including mesenteric vascular bed 
(Tesfamariam & Halpem, 1987) based on the failure of acetylcholine to dilate the 
vessel after CHAPS, and electron microscopic examination. In the present study,
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there was a small increase in perfusion pressure during the infusion of CHAPS which 
would probably suggest denudation of the endothelium. Loss of endothelial function 
was confirmed by the failure of carbachol to evoke a dilatation following CHAPS. 
However, vasoconstrictor responses to low doses of NA were not enhanced by 
CHAPS treatment whereas responses to higher doses of NA were reduced 
significantly. The reduction in vasoconstrictor responses could not have been due to a 
non-specific destruction of the vascular smooth muscle since the vasoconstrictor 
effects of KC1 were not affected by CHAPS treatment. It is therefore possible that the 
reduction in NA-induced vasoconstriction following endothelium removal by 
CHAPS could suggest an involvement of an endothelium-derived contracting factor 
in the vasoconstricting effect of NA. On the other hand, NA-induced vasoconstriction 
was potentiated by L- NOARG, an NO-synthase inhibitor (Moore et al., 1990) 
indicating that NA-induced vasoconstriction was accompanied by a release of 
endothelium-derived relaxing factor. L-NOARG, has been shown to produce a 
reversible inhibition of the vasoconstrictor effect of Ach in rabbit aortic rings and the 
rat perfused mesentery (Moore et al., 1989; 1990). An explanation was that NA had 
two sites of activity on the normal vessel wall; to contract the smooth muscle and to 
release EDRF. EDRF would then behave as a functional antagonist of the contractile 
signal following a-adrenoceptor activation. L-NOARG also has some affinity for the 
inducible NOS (iNOS) (McCall et al., 1991). Therefore, there is the possibility that L- 
NOARG could have potentiated NA-induced vasoconstriction by inhibiting iNOS 
activity. If this were to be true, aminoguanidine, a more selective inhibitor of iNOS 
(Misko et al., 1993), (with no activity on cNOS), should also enhance NA-induced 
vasoconstriction. However, no enhancement of NA-induced responses was observed 
following perfusion of the vascular bed with aminoguanidine. Thus inhibition of 
iNOS is not involved in L-NOARG enhancement of NA-induced vasoconstriction in 
this vascular bed. This is supported by the following observations: (1) four 
consecutive NA dose-response curves (at lhr intervals) could be obtained without any 
reduction in potency or maximum response (the absolute response tended to increase), 
and (2) L-NOARG had no effect in endothelium-denuded preparations. So it is quite 
possible that both endothelium derived relaxing and contracting factors (EDRF & 
EDCF) modulate the response to NA (in particular at the high doses) in the perfused
ovarian vascular bed with a predominance of the EDCF contribution. Thus removal of 
the endothelium would remove the modulating effect of both EDCF and EDRF, and 
hence the response to NA would be reduced. On the other hand, treatment with NO- 
synthase inhibitor would remove only the inhibitory effect of EDRF leading to an 
enhanced response to NA. In the perfused rabbit ovarian vascular bed (this study), 
carbachol induced a dose-dependent vasodilator effect of the ovarian vascular bed pre­
constricted by NA. This contradicts earlier reports by Graham & Sani (1971) who 
only observed vasoconstriction to acetylcholine even when perfusion pressure was 
raised with NA. The reason for this discrepancy is not known. However, in the 
present study, NA (10’5M) was used to raise the perfusion pressure as opposed to a 
concentration of 2xlO'6M used by Graham & Sani (1971). It is possible that 
carbachol-induced vasodilation is dependent on the level of tone existing in the 
preparation. Carbachol-induced vasodilatation was abolished by inhibitors of 
cyclicGMP production, LY 83583 (Mulsch et al., 1988; Fleming et al., 1991) and 
methylene blue (Mayer et al., 1993), confirming that it is mediated via generation of 
cyclicGMP. The results so far would confirm that carbachol-induced an endothelium- 
dependent vasodilation which involves cyclicGMP generation. The same 
concentration of L-NOARG which enhanced NA-induced pressor responses reduced 
but did not abolish the vasodilator responses to carbachol indicating that carbachol- 
induced vasodilation is only partly dependent on NO generation. Frew et al. (1993) 
also reported an inhibition of ACh-induced relaxations by L-NOARG in rat aorta. 
Considerable evidence shows that, in addition to endothelium-derived nitric oxide, 
Ach and a variety of other agents release a factor that causes vascular smooth muscle 
relaxation through the release of an hyperpolarizing factor, EDHF (Chen et al., 1988; 
Komori & Vanhoutte, 1990). It has been demonstrated that ACh and other 
muscarinic agonists stimulate endothelium-dependent smooth muscle 
hyperpolarization (Bolton et al., 1984; Garland & McPherson, 1992; Chen et al.,
1988). ACh-induced hyperpolarization was not blocked by EDRF inhibitors such as 
methylene blue and oxyhaemoglobin (Chen et al., 1988; Taylor & Weston, 1988). 
Even though both carbachol and SNP act via NO accumulation, only carbachol 
stimulates NO production through cNOS activity. Thus it is to be expected that L- 
NOARG would not affect vasodilatation-induced by SNP. This was observed in the
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ovarian vascular bed as vasodilatation induced by SNP was not affected by L- 
NOARG. Interestingly, LY 83583 and methylene blue, also had no effect on SNP- 
induced vasodilatation, suggesting that cyclicGMP generation may not be involved in 
this action of SNP. Earlier studies have shown that SNP is a receptor-operated Ca2+ 
channel antagonist (Karaki et al., 1985; 1988b). This could account for SNP-induced 
vasodilatation observed in this study. Similarly, isoprenaline induces vasodilatation 
mainly by activating adenyl cyclase leading to accumulation of cyclicAMP (Furchgott 
& Vanhoutte, 1989). Recent reports, however; tend to indicate that isoprenaline can 
also stimulate guanylate cyclase leading to accumulation of cyclicGMP. It has been 
shown, at least in ring segments of the rat aorta that isoprenaline-induced relaxation is 
accompanied by elevated levels of cyclicGMP (Gray & Marshall, 1992). The same 
authors also showed that L-NOARG significantly reduced isoprenaline-induced 
relaxation confirming that NO release is involved. In the ovarian vascular bed, 
however; isoprenaline-induced vasodilatation was not affected by L-NOARG and not 
significantly affected by LY 83583. This would indicate that isoprenaline induced 
vasodilatation of the rabbit ovarian vascular bed independently of NO and cyclicGMP. 
It is therefore concluded that there is little or no basal release of NO in the perfused 
ovarian vascular bed, since L-NOARG alone did not raise the basal perfusion pressure. 
However, NA-induced contractions are accompanied by NO release which limited the 
contractions since inhibition of cNOS led to increased response to NA. Carbachol 
induced vasorelaxant responses, though dependent on cyclicGMP accumulation, were 
significantly reduced but not abolished by L-NOARG, indicating that it was not totally 
mediated via NO. It is therefore, concluded that the relaxant effects may be mediated 
via both endothelium-derived NO and EDHF.
43 Adrenergic receptors in the ovarian circulation
43.1 a- or 0-Adrenoceptors
NA responded with a vasoconstriction in the rabbit ovarian vascular bed. The 
profound inhibitory effect of phentolamine on NA-induced vasoconstriction, clearly 
demonstrated the involvement of a-adrenoceptors. The failure of propranolol to 
modulate NA-induced vasoconstriction could be due to either of two possibilities; (1) 
that there are no B-adrenoceptors in the rabbit ovarian circulation or (2) that B-
138
adrenoceptors, though present are not functional. Experiments were therefore 
performed to test for the presence or otherwise of B-adrenoceptors in the ovarian 
vascular bed. When the perfusion pressure was raised with NA (or methoxamine), 
isoprenaline (at high doses) induced dose-dependent reductions in perfusion pressure 
probably suggesting that there are B-adrenoceptors in the ovarian vascular bed. Varga 
et al, (1979) have also observed B-adrenoceptor mediated vasodilation in the human 
ovarian bed. However, isoprenaline-induced vasodilation in the ovarian vascular bed 
was not significantly affected by propranolol (lQ^M and 10’5M), indicating that 
atypical rather than conventional Br  and B2-adrenoceptors probably mediated this 
response. It is also possible that isoprenaline-mediated vasorelaxation could be due to 
a-adrenoceptor blockade. In order to test this possibility, perfusion pressure was 
raised with U46619 (a thromboxane mimetic agent) or histamine instead of NA. 
Under this condition, isoprenaline produced pressor responses at all doses. The 
pressor responses were blocked by phentolamine, indicating involvement of a- rather 
than B-adrenoceptors, thus confirming the absence of B-adrenoceptors in the rabbit 
ovarian vascular bed.
43.2, a t- or a 2-Adrenoceptors
It is now widely accepted that the post-junctional effects of a-adrenergic agonists are 
mediated by a r  and a 2-adrenoceptors, both of which are equipotently antagonized by 
phentolamine (Nichols & Ruffolo, 1991). As described above, NA-induced 
vasoconstriction was potently antagonized by phentolamine. Therefore, in order to 
identify the a-adrenergic receptors present in the ovarian vascular bed, the interactions 
between selective antagonists prazosin (aj) and yohimbine (a2) with adrenergic 
agonists were investigated. NA, methoxamine, phenylephrine, SDZ NVI 085 and 
oxymetazoline produced dose-dependent vasoconstriction of the perfused ovarian 
vascular bed, while clonidine, tizanidine, B-HT 920 and UK 14,304 were not 
effective. This would probably suggest that a  t-adrenoceptors mediated 
vasoconstriction. However, the possibility of a minor contribution of a 2- 
adrenoceptors can not be ruled out. Thus a simultaneous activation of a 2- 
adrenoceptors could have contributed to the effect of NA. Although a 2-adrenoceptor- 
mediated vasoconstriction is readily demonstrable in vivo and in vitro using venous 
smooth muscle (Matthews et al., 1984; ), it is generally difficult to demonstrate a 2-
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adrenoceptor mediated responses in arterial smooth muscles in vitro (Skarby et al., 
1983; Sulpizio & Hieble, 1987). However, a definite and concentration dependent 
response is usually unmasked in the presence of an elevated tone using constrictor 
agents like vasopressin, angiotensin and Bay K 8644 (Templeton et al., 1989; 
Bohmann et al., 1995). This protocol was also used in this study in an attempt to 
unmask any a 2-adrenoceptor mediated vasoconstriction. Clonidine, tizanidine, B-HT 
920 and UK 14,304 did not produce any significant vasoconstrictor effect in 
preparations in which perfusion pressure was raised with methoxamine, NA or 
U46619. It is therefore unlikely that there are postjunctional a 2-adrenoceptors 
mediating vasoconstriction in the ovarian vascular bed. Blue and Clarke (1990) also 
could not demonstrate a 2-adrenoceptors mediated responses in the perfused rat kidney 
even when perfusion pressure was elevated with angiotensin II. Further support for 
aj-adrenoceptor mediated responses in the ovarian vascular bed was obtained from 
antagonist studies. Prazosin, concentration-dependently antagonized NA-induced 
vasoconstrictions. There was a parallel rightward shift of the NA dose-response curve 
without a reduction in the maximum response. The pA2 value was 7.35 and the slope
l.Q±0.1, the latter was not significantly different from 1, indicating competitive 
antagonism. This observed pA2 value was very low compared to values reported in 
the literature (Agrawal et al., 1984). The reason for this low potency is at present not 
known. However, a similar low pA2 value (<8.0) was obtained in ring segments of the 
ovarian artery (Oriowo & Bevan, 1986), probably indicating that a  j-adrenoceptors in 
the ovarian circulation have a low affinity for prazosin. Oxymetazoline, 
phenylephrine, methoxamine and SDZ NVI 085 were all antagonized by prazosin. 
Except for oxymetazoline, the pA2 / pKB values recorded for these agonists were 
found to be similar to the value for NA. The pA2 value for prazosin against 
oxymetazoline was lower than its potency against the other agonists. The reason for 
this is not known. However, a similar observation has been made in the rabbit prostate 
gland (Sulpizio A., personal communication). Yohimbine, a selective a 2-adrenoceptor 
antagonist, antagonized NA-induced vasoconstriction, but only at a high 
concentration. The kB value (obtained using 10’5M yohimbine) was 7.1xlO‘6M. The 
prazosin/yohimbine ratio was approximately 100, which is still consistent with 
activation of a!-adrenoceptors in spite of the low potency of prazosin in this
preparation. Phenylephrine was also not antagonized by yohimbine, therefore, a r  
but not a 2-adrenoceptors mediated vasoconstriction in the perfused rabbit ovarian 
vascular bed.
The results also showed that a  t -adrenoceptors-mediated vasoconstrictor responses to 
electrical stimulation. Transmural electrical stimulation at supramaximal voltage 
induced a frequency-dependent vasoconstriction of the ovarian vascular bed. The 
vasoconstrictor responses were abolished by 6-OHDA indicating that they were 
adrenergic in origin. Prazosin produced a significant concentration-dependent 
reduction of the electrically evoked response suggesting that a!-adrenoceptors were 
involved. Yohimbine at 10'5M, reduced the responses to electrical stimulation by 
15%. However, this concentration of yohimbine is similar to the concentration at 
which yohimbine blocks a  j-adrenoceptors.
4.3.3 Subtype(s) of aj-adrenoceptors
Within the past ten years, there have been a number of reports showing heterogeneity 
of aj-adrenoceptors in different tissues, vascular and non-vascular (McGrath, 1982; 
Morrow & Creese, 1986; Flavahan & Vanhoutte, 1986). Based on the differential 
affinities of vascular smooth muscle preparation to prazosin and yohimbine, Flavahan 
and Vanhoutte (1986) subdivided a  j-adrenoceptors into a 1H- and a 1L-subtypes. This 
sub-classification was later expanded by Muramatsu and coworkers (Muramatsu et al., 
1991) to include a third subtype, a 1N which also has a low affinity for prazosin. This 
existence of this subtype was based on the varying affinity of the tissues for HV 723; 
which is selective for a 1N-subtype. ai-Adrenoceptors were also classified into a 1A-and 
a 1B-subtypes based on their differential sensitivities to a number of antagonists (Han 
et al., 1987; Minneman 1988). a 1A-adrenoceptors are activated by phenylephrine, 
methoxamine and SDZ NVI 085 (Eltze & Boer, 1992) and are potently antagonized 
by WB-4101 (Kb= 9.0), 5-methylurapidil and (+)-niguldipine (Han et al., 1987). They 
are not inactivated by the clonidine analogue CEC, but are inactivated by SZL-49 
(Piascik et al., 1990). a 1B-adrenoceptors, on the other hand, are less sensitive to 
WB-4101 (Kb < 8) but are inactivated by CEC (Han et al., 1987). Later studies have 
identified two more subtypes of the a  j -adrenoceptors. These are a lc-(Schwinn et al., 
1991) and a 1D-subtypes (Perez et al.,1991). So far, the functional significance of these 
ctj-adrenoceptor subtypes are not known. Both a lc- and a 1D-subtypes are potently
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antagonized by WB-4101 (=(Xia) (Lomasney et al., 1991) and are also inactivated by 
CEC (a lc- not significantly). In the perfused rabbit ovarian vascular bed, NA-induced 
vasoconstriction was competitively antagonized by WB-4101. But the pA2 value 
(7.93) was much lower than what would be expected at a IA-, a lc- or a 1D-adrenoceptor 
subtypes indicating that a 1B receptors might mediate NA-induced vasoconstriction in 
the ovarian vascular bed. However, NA-induced vasoconstriction was not affected by 
CEC but was remarkably inhibited by SZL-49. This would suggest that a 1B- and a 1D- 
adrenoceptor subtypes are possibly not involved in NA-induced responses in the 
ovarian vascular bed. The reason for the low pA2 value for WB-4101 is unknown. 
Perhaps the same reason might explain the low prazosin pA2 value too. The a r  
adrenoceptors were found to be activated by phenylephrine, oxymetazoline, 
methoxamine and SDZ NVI 085 and the agonists-induced vasoconstriction were 
competitively antagonized by WB-4101. The a m-selective antagonist CEC, did not 
have any effect on NA- and oxymetazoline-dose response curves. The agonists- 
induced vasoconstriction was inhibited by the a 1A-selective antagonist SZL-49. There 
was a highly significant rightward shift of the agonists-dose response curve, indicating 
involvement of a 1A-adrenoceptor subtype. Since both a lc- and a 1D-subtypes are 
potently antagonized by WB 4101 (Lomasney et al., 1991) and are also inactivated by 
CEC, this would suggest that a 1B-, a lc- and a iD-adrenoceptor subtypes are not 
involved in agonist-induced responses in the ovarian vascular bed. The fact that SZL- 
49 significantly reduced agonist-induced vasoconstrictor responses would strengthen 
the suggestion that a 1A-adrenoceptor subtype mediated agonist-induced 
vasoconstrictor response in the ovarian vascular bed. (+)-Niguldipine is highly 
selective antagonist of the a 1A-adrenoceptor subtype (Gross et al., 1988). Therefore, 
the observation in this study that (+)-niguldipine at a low concentration (10'9M) 
abolished the pressor response to NA would further confirm that a 1A-subtype 
mediated agonist responses in the ovarian vascular bed.
WB-4101, concentration-dependently reduced the electrically-induced response. This 
together with the fact that SZL-49 but not CEC reduced the response, would confirm 
that a 1A-adrenoceptors mediated the vasoconstrictor response to electrical stimulation.
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A4.4 Signal transduction mechanism
The relative role of extracellular calcium influx and intracellular calcium release in the 
coupling of a !-adrenoceptor activation to response have been the subject of much 
controversy for many years. Pressor responses in vivo mediated by postjunctional 
vascular a!-adrenoceptors were found to be resistant to inhibition by calcium channel 
antagonists (Cavero et al., 1983 & van Meel et al., 1981), suggesting that, a r  
adrenoceptors may not rely heavily upon extracellular calcium to produce
vasoconstriction. However, partial -adrenoceptor agonists evoked responses that are
2+affected by Ca channel antagonists indicating that a  j-adrenoceptor activation could
2+also be linked to transmembrane influx of Ca . This has been supported by studies
2+measuring Ca fluxes in vascular smooth muscles which showed that a r adrenergic
21 2+agonists promote Ca influx and release of intracellular Ca (Deth & Lynch, 1981;
Cauvin et al., 1982; Chiu et al., 1986). Experiments were therefore performed to
2+determine the source(s) of activator Ca utilized by adrenergic agonists in ovarian 
vascular bed.
The results showed that there was a significant reduction in response to NA when
perfused with a nominally Ca2+-free KH-solution and also that the residual responses
2+were abolished in Ca -free KH-solution containing EGTA, suggesting the
involvement of both influx of extracellular Ca and release of (probably membrane
2+bound) intracellular Ca in the vasoconstrictor response to NA. The results also
showed that vasoconstrictor response to a fixed dose (300 nmoles) of NA was lost
2+within 60 min in a Ca -free medium. The half life was 4 min, which was reduced to
2.5 min in the presence of EGTA (2mM). This could probably suggest that Ca2+ 
stored in a labile pool (and probably of limited capacity) contributed to the response to 
NA. On returning to a normal KH-solution, more than 40% of the response to NA 
was restored within the first 5 min while 100% responsiveness was attained within 15 
min indicating that the store is easily filled with Ca2+. The calcium channel blockers 
verapamil and nifedipine produced a concentration dependent reduction in the 
vasoconstrictor response to NA. However, even at a concentration of 10"5M, none of
these agents abolished NA-induced vasoconstriction. This would be consistent with
2+the assumption that both extra- and intracellular sources of Ca are involved in NA- 
induced responses. In support of this, is the observation that KCl-induced
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vasoconstrictor responses were abolished by verapamil and nifedipine at a 
concentration of 10'6M, confirming that KCl-induced vasoconstriction was solely 
dependent on an influx of extracellular Ca2+. Bolton (1979) originally identified two 
types of Ca2+ channels, voltage operated (VOC) and receptor-operated (ROC) 
channels differing in their sensitivities to Ca2+ channel antagonists. VOCs are more 
susceptible to Ca2+ channel antagonists (eg. verapamil) than are ROCs. Ca2+ 
mobilization by NA in the ovarian vascular bed is consequent upon its combining with 
ai-adrenoceptors on the membrane and thus involves receptor operated channels. 
The fact that verapamil and nifedipine are more potent against KC1 (which involves 
depolarization)-induced vasoconstriction would tend to support this hypothesis. In 
addition, SNP, a ROC inhibitor (Karaki et al., 1985) at 1000 nmoles, abolished NA- 
induced vasoconstrictor response, would confirm that NA evoked vasoconstrictor 
responses by activating ROCs. There are reports in the literature that partial agonists 
are more sensitive to inhibition by Ca2+ channel inhibitors than full agonists (Nichols 
& Ruffolo, 1988; Ruffolo et al., 1984; Oriowo et al., 1990, 1992), suggesting that 
agonist efficacy determines the sensitivity of a response to Ca2+ channel inhibitors. 
This is further supported by the observation that pretreatment with phenoxybenzamine 
to reduce the efficacy of full agonists, resulted in enhanced sensitivity of the full 
agonsit to the antagonist effect of Ca2+ channel inhibitors (Ruffolo, 1984; Nichols & 
Ruffolo, 1988). This was tested in this study by examining the effect of verapamil and 
nifedipine on SDZ NVI 085-induced vasoconstriction. This agent was a partial 
agonist in the ovarian vascular bed (this study) producing 74% of NA-maximum. The 
results showed that verapamil and nifedipine, inhibited SDZ NVI 085-induced 
vasoconstrictions. However, neither verapamil nor nifedipine was more effective 
against SDZ NVI 085 relative to NA, indicating that agonist efficacy does not affect 
sensitivity to Ca2+ channel inhibitors in this preparation.
Similar observations have been made in the rabbit thoracic aorta segments where 
clonidine-induced contractions (Emax = 54% of NA maximum) were not more 
sensitive to nifedipine than were NA-induced contractions (Oriowo, personal 
communications).
Functional assessment of the role of SR in contraction is difficult. It has often 
involved measurements of contraction in Ca2+-free media, which eliminates Ca2+ entry
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(Devine et al., 1972) but may also deplete Ca2+ stores and, in the presence of caffeine, 
unloads the SR Ca2+ store (Leijten & van Breemen, 1984). Ryanodine, a plant
2+ 2+
alkaloid, depletes the SR Ca store by opening SRCa release channels (Hwang & 
van Breemen, 1987). Ryanodine does not affect plasma membrane Ca2+ channels 
(Lattanzio et al., 1987), nor does it affect the contractile apparatus or the sarcolemmal 
Ca2+ transport mechanisms (Sutko et al., 1985). Therefore, this alkaloid appears to be 
useful for assessing the relative role of the SR in vascular smooth muscle contraction 
(Shima & Blaustein, 1992) and was chosen in this study to assess the role of 
intracellular calcium in mediating the vasoconstrictor responses to NA. The results 
showed that ryanodine (up to 10'5M) had little or no effect on the vasoconstrictor
response to NA. This would therefore suggest that NA-induced vasoconstrictions in
2+the ovarian vascular bed is not dependent on Ca release from the SR. 
a  j-Adrenoceptor activation is associated with the hydrolysis of membrane-bound 
inositol phosphate resulting in the generation of Ins(l,4,5)P3 and DAG. Ins(l,4,5)P3 
releases Ca2+ from intracellular stores (Berridge, 1984; 1987) while DAG activates 
PKC (Nishizuka, 1986). Activation of PKC produces contractions via an influx of 
extracellular Ca2+. Since it has been shown in the previous sections that a r  
adrenoceptor activation in the rabbit ovarian vascular bed promotes an influx of 
extracellular Ca2+ , an attempt was made to determine whether activation of PKC was 
involved in this phenomenon. This was done by examinig the effects of two inhibitors 
of PKC, HA-1077 (Asano et al., 1989) and polymyxin B (Miller et al., 1986; Khalil & 
van Breemen, 1988) on NA-induced vasoconstriction in the ovarian vascular bed. The 
results showed that HA-1077 produced a concentration-dependent inhibition of NA- 
induced responses associated with a suppression of the maximum response. Perhaps 
this would suggest an involvement of PKC activation in NA-induced vasoconstrictor 
response. However, this is not supported by the failure of polymyxin B even at a 
concentration of 10-4 M, to significantly reduce NA-induced vasoconstriction. It is
quite possible that other factors could have been responsible for the inhibitory effect of
2+
HA-1077. For example, HA-1077 has been shown to inhibit Ca influx as well as
2+
reduce sensitivity of the contractile elements to Ca (Asano et al., 1987). This has
2+
been confirmed in the present study on the ovarian vascular bed, where Ca -induced
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contractions of high K+-depolarized preparations were significantly attenuated by HA- 
1077 but not by polymyxin B.
Evidence have accumulated over the past ten years that tyrosine kinases can also 
participate in signal transduction mechanisms. They have been shown to be involved 
in cell proliferation and transformation (Bishop, 1987; Draetta et al., 1988), 
regulation of neurotransmitter receptors (O’Dell et al., 1991) and initiation of 
mitogenic responses by certain growth factors (Dvir et al., 1991; Ullrich & 
Schlessinger, 1990). Di Salvo et al (1988; 1989) have shown that smooth muscles 
contain unusually high levels of TK activity, raising the possibility that TK activity 
could be important for the growth response and possibly contractile response of 
smooth muscles. Later studies have shown that TK inhibitors, e.g. genistein (Akiyama 
et al., 1987; Casnellie, 1991) and tyrphostin (Levitzki & Gilon, 1991; Casnellie, 1991) 
inhibited agonist-induced contractions in several smooth muscles including carotid 
artery, guinea pig taenia coli and mesenteric microvessels, rat mesenteric resistance 
arteries and thoracic aorta (Toma et al., 1995; Di Salvo et al., 1993; Adeagbo & 
Triggle, 1993). The possible involvement of TK activation, in signal transduction 
pathway in the ovarian vascular bed, was examined by studying the effect of genistein 
on NA-induced vasoconstrictor responses. The results showed that genistein 
concentration-dependently inhibited NA-induced vasoconstriction. Genistein and 
other TK inhibitors have been shown to be specific in their action. They do not affect 
MLCK or cyclicAMP-dependent kinases, and also had no effect on direct activation 
of the contractile apparatus (Di Salvo et al., 1993). Therefore, inhibition of NA- 
induced vasoconstriction by genistein in the ovarian vascular bed would suggest an 
involvement of TK activation in the NA-induced vasoconstriction.
4.5 Hormonal influences on the ovarian vasculature
A greater predominance of cardiovascular diseases in young women would suggeset a 
role for sex hormones in the pathogenesis of these disorders. Women taking oral 
contraceptives are more prone to hypertension (Laragh et al., 1972; Fregly, 1972; 
Kaplan, 1978). This is believed to be due to the oestrogenic component of the pill 
(Wallace, 1971). In support of this, is the observation that chronic treatment of rats 
with oestrogens induces and maintains hypertension (Bhatt & Gulati, 1986). In vitro,
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vascular smooth muscle reactivity has been shown to be enhanced by oestrogen 
pretreatment. Altura (1972) showed that terminal mesenteric arterioles from female 
rats were more potently contracted by catecholamines than were similar preparations 
from male rats. Farhat and Ramwell (1992) have observed that perfused lung 
preparations from female rats were significantly more responsive to U46619 than 
similar preparations from age-matched male rats. This have been confirmed by other 
investigators including Bento and DeMoreas, 1992; Austin and Chess-Williams, 
1995; Vargas et al., 1995 and Ma etal., 1996. This would provide further evidence for 
the role of female sex hormones in modulating vascular smooth muscle reactivity.
The effect of oestrogen pretreatment, in vitro and in vivo, on reactivity of the ovarian 
vascular bed to a  j-adrenergic agonists was therefore examined. The results obtained 
in these studies showed that oestradiol-17B, administered in vitro produced a 
significant concentration dependent reduction in NA-induced vasoconstrictor 
responses. This was characterized more by a depression of the maximum response,
while there was only a slight rightward shift of the dose-response curves. This could
2+
probably be due to an inhibitory effect of oestradiol-17B on Ca influx. Oestradiol- 
17B has been shown to inhibit Ca2+ influx in several preparations including rat aorta 
(Vargas et al., 1989), rabbit heart (Raddino et al., 1986) and uterine arterial smooth 
muscle cells (Stice et al., 1987). However, ovarian vascular bed, isolated from 
rabbits treated with oestradiol-17B propionate, exhibited significantly enhanced 
pressor response to NA and oxymetazoline indicating that oestradiol might be acting 
at the genomic level. Unlike in the mesenteric bed (Vargas et al., 1995) or lung 
preparation (Farhat & Ramwell, 1992) where oestradiol produced a leftward shift of 
NA dose-response curve and an increase in maximum response, oestrogen-induced 
enhancement of NA response in the ovarian vascular bed was characterized only by a 
leftward shift of the dose-response curve without a significant change in the maximum 
response. In addition, the increased sensitivity appeared to be specific for a- 
adrenergic agonists. Thus while the potencies of NA and oxymetazoline were 
increased, the potency of histamine in inducing vasoconstriction was unchanged.
Two other situations associated with increased plasma concentrations of oestradiol, 
ovulation induction and pregnancy also enhanced vasoconstrictor responses to NA and 
oxymetazoline but not histamine.
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The increased sensitivity of the ovarian vascular bed to a  j-adrenergic agonists under 
conditions of oestrogen dominance could be due to a number of factors including, (1) 
oestrogen inhibition of uptake mechanisms, (2) increase in agonist affinity and/or 
receptor density or (3) increased availability of Ca2+.
It is well recognized that steroids inhibit uptake2  process (Iversen & Salt, 1970) in 
adrenergically innervated tissues. It is however unlikely that inhibition of uptake2  
would explain oestradiol-induced potentiation of NA response, since in preliminary 
experiments, it was shown that an inhibition of uptake2  (DOCA) did not modulate 
NA-induced vasoconstrictor responses.
The potency of a!-adrenergic agonists in inducing vasoconstriction is determined by 
two factors, affinity for the receptors and receptor density. Bevan et al (1986) showed 
that there is a direct correlation between potency of NA and its affinity for a r  
adrenergic receptors in a number of rabbit arteries. In the cat however, receptor 
density rather than affinity seems to be the main determinant of agonist potency 
(Oriowo et al., 1989). Radioligand binding studies have shown that oestrogen-induced 
potentiation of NA vasosonstriction in rat mesenteric arteries is associated with an 
increase in agonist affinity but not receptor density (Colucci et al., 1982). Functional 
studies on the same tissue showed that NA dose-response curve was shifted to the left, 
however, the maximum response remained unchanged. In the perfused rabbit ovarian 
vascular bed, no radioligand binding studies have been done and so no definitive 
statement can be made about changes (or not) in agonist-affinity or receptor density. 
However, the characteristics of the change, leftward shift in NA dose-response curve 
without an increase in the maximum response, is characteristic of an enhanced 
sensitivity due to an increase in agonist-affinity. Laher and Bevan (1985) have shown 
that receptor number (density) determines the maximum response to an agonist Thus 
it is most likely that the increased sensitivity of the ovarian vascular bed to otj- 
adrenergic agonists following treatment with oestradiol-17B-propionate, or ovulation 
induction and pregnancy could be due to oestradiol-induced increase in agonist 
affinity for the receptors.
Austin and Chess-Williams (1995) observed a significant increase in vascular a 2-but 
not a  j-adrenoceptor responsiveness following treatment of rats with 17B-oestradiol. 
In order to test whether functional a 2-adrenoceptors were unmasked following
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hormone manipulation, the effect of yohimbine and B-HT 920 were tested against 
NA-induced vasoconstriction in preparations obtained from pregnant rabbits only 
(since there was no qualitative or quantitative difference in the responses to NA in 
different groups of the rabbits). It was observed that B-HT 920, an a 2-adrenoceptor 
agonist, did not produce vasoconstrictor responses. This coupled with the weak 
antagonist potency of yohimbine against vasoconstriction induced by NA, would 
confirm that a 2-adrenoceptors do not contribute to NA-induced responses. Further 
studies also showed that there was no change in a!-adrenoceptor subtype. NA- 
induced vasoconstriction was resistant to CEC but attenuated by SZL-49 indicating 
that a 1A-adrenoceptors (as in the control rabbits) mediated NA responses in conditions 
of oestrogen dominance.
Endothelial dysfunction could also be a contributing factor to enhanced 
vasoconstrictor activity. This has been shown in experimental hypertensive rats, 
where impaired endothelial function was associated with increased vascular reactivity 
(Sunano et al., 1989). In the perfused ovarian vascular bed, treatment with oestrogens, 
ovulation induction and pregnancy are associated with increased sensitivity of the 
preparations to NA (this study). L-NOARG did not significantly enhance NA-induced 
vasoconstrictions in any of these situations. This is contrary to the significant 
potentiation of NA responses by L-NOARG in control rabbits. Perhaps this 
observation would suggest endothelial dysfunction in these hormonal states. 
However, this is unlikely to be the case. There are several reports in the literature, that 
oestrogen treatment and pregnancy improves endothelium-dependent vasodilatation. 
For example, Bell (1973) and Graham and Sani (1971) have shown that endothelium- 
dependent vasodilator responses to acetylcholine in the guinea pig uterine artery and 
rabbit uterine and ovarian arteries, were unmasked during pregnancy. In addition, it 
has been shown that oestrogen-treatment increases basal release of nitric oxide in ring 
segmants of the rat aorta (Rahimian et al., 1996) and increases arterial relaxation in 
mesenteric arteries (Ferrer & Osol, 1996).
In this study, the vasoconstrictor response to oxymetazoline, a partial a r  
adrenoceptors agonist, was enhanced by L-NOARG in the ovarian vascular bed 
preparations from pregnant rabbits (in the same preparation where L-NOARG failed to 
enhance NA responses). In addition, there was no significant difference between the
149
vasodilator potencies of carbachol in control rabbits and hormone-treated (or pregnant) 
rabbits. The maximum relaxation was also not different. Perhaps more significantly, 
carbachol-induced vasodilation was abolished by L-NOARG, indicating that NO is 
totally responsible for the vasodilator effect of carbachol.
Therefore, failure of L-NOARG to enhance NA-induced vasoconstriction in the 
hormone treated rabbits (including pregnancy) could possibly be due to the fact that 
under these conditions, the response to NA was already maximally potentiated, so that 
no further potentiation could be obtained in the presence of L-NOARG. In support of 
this, is the fact that ED50 (for NA) obtained in preparations from hormone-treated 
rabbits was not significantly different from the value obtained in control rabbits, in the 
presence of L-NOARG.
4.6 Conclusion
Based on the results obtained in this study, it was concluded that:
(1) The ovarian vascular bed responded to adrenergic agonists with a 
vasoconstriction.
(2) There is little or no basal release of NO. However, the vasoconstrictor 
response to NA was accompanied by a release of NO resulting in reduced 
response to NA.
(3) a r  But not a 2-adrenoceptors mediated NA-induced vasoconstriction in this 
vascular bed.
(4) The a r adrenoceptor is of the a 1A-subtype.
(5) a iA-adrenoceptor activation in the rabbit ovarian vascular bed is linked to an
2+
influx of extracellular Ca through activation of tyrosine kinase.
(6) Oestrogen treatment, ovulation induction and pregnancy are all associated 
with an a  j-adrenoceptor specific increase in sensitivity of the ovarian 
vascular bed to NA and oxymetazoline. However, there was no change in 
receptor characteristics, i.e. a 2-adrenoceptor was not unmasked and the 
vasoconstrictor responses were still mediated via a 1A-adrenoceptor subtype.
(7) There was no enhanced vasodilator response to carbachol indicating that 
there was no increased release of EDRF accompanying the changes in
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hormone status. However, L-NOARG abolished carbachol-induced 
vasodilatation indicating that NO mediated the response.
In summary, the enhanced sensitivity of the ovarian vascular bed to noradrenaline 
following induction of ovulation and pregnancy could be of physiological relevance. 
The ovarian arteiy gives off a branch which supplies the oviduct and continues to join 
the uterine arteiy. Development of the ovum begins in the proximal part of the 
oviduct and it is therefore essential that there must be an adequate blood supply to this 
region to provide nutrients to the developing ovum. Therefore, increased 
vasoconstriction in the ovarian vascular bed would divert blood flow towards the 
proximal part of the oviduct. This would result in increased supply of nutrients to the 
developing embryo. Similarly, during pregnancy, there is no need for ovulation to 
take place and so diversion of blood flow away from the ovary would lead to increased 
perfusion of the uterus and hence supply of nutrients to the growing fetus. This would 
perhaps be more significant in humans where a good part of the blood supply to the 
uterus is through the ovarian artery.
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